

CITATION REPORT

List of articles citing

Pharmacologic therapy for type 2 diabetes mellitus

DOI: 10.7326/0003-4819-131-4-199908170-00008
Annals of Internal Medicine, 1999, 131, 281-303.

Source: <https://exaly.com/paper-pdf/30650979/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
835	Medical costs of managed care in patients with type 2 diabetes mellitus. 1999 , 21, 2131-42		19
834	Pharmacologic therapy for type 2 diabetes mellitus. <i>Annals of Internal Medicine</i> , 2000 , 133, 73-4	8	64
833	Emerging concepts in metabolic abnormalities associated with coronary artery disease. 2000 , 15, 416-21		44
832	Prevention of coronary heart disease by raising high-density lipoprotein cholesterol?. 2000 , 11, 627-37		76
831	Making a case for inclusion of new oral anti-diabetic agents in drug formularies. 2000 , 17, 141-146		
830	Physiology of glucose homeostasis. 2000 , 2, 345-50		99
829	New approaches in the treatment of type 2 diabetes. 2000 , 4, 461-7		164
828	Human liver glycogen phosphorylase inhibitors bind at a new allosteric site. 2000 , 7, 677-82		95
827	Oral medications for treating diabetes mellitus in dogs and cats. 2000 , 41, 486-90		9
826	Diamicron MR once daily is effective and well tolerated in type 2 diabetes: a double-blind, randomized, multinational study. 2000 , 14, 185-91		30
825	Effects of dietary restriction on insulin resistance in obese mice. 2000 , 23, 95-101		
824	New therapies in diabetes [Thiazolidinediones]. 2000 , 5, 441-456		7
823	Effect of the alpha-glucosidase inhibitor acarbose on control of glycemia in dogs with naturally acquired diabetes mellitus. 2000 , 216, 1265-9		8
822	Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. 2000 , 22, 1395-409		314
821	Potential new treatments for type 2 diabetes. 2000 , 21, 259-65		61
820	Addressing the insulin secretion defect: a logical first-line approach. 2000 , 49, 12-6		10
819	Glipizide. A review of the pharmacoeconomic implications of the extended-release formulation in type 2 diabetes mellitus. 2000 , 18, 289-306		24

818	Beneficial and detrimental effects of intensive glycaemic control, with emphasis on type 2 diabetes mellitus. 2000 , 17, 463-76	11
817	Diabetes mellitus and closed-loop insulin delivery. 2000 , 17, 455-96	8
816	Prevalence of non-diabetic renal disease among African-American patients with type II diabetes mellitus. 2000 , 34, 331-5	28
815	A rational approach to drug therapy of type 2 diabetes mellitus. 2000 , 60, 95-113	81
814	Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus. 2001 , 61, 1625-60	95
813	Perioperative care of diabetic patients. 2001 , 18, 277-94	17
812	High glucose causes apoptosis in cultured human pancreatic islets of Langerhans: a potential role for regulation of specific Bcl family genes toward an apoptotic cell death program. 2001 , 50, 1290-301	267
811	The effect of 3-month ingestion of Ginkgo biloba extract (EGb 761) on pancreatic beta-cell function in response to glucose loading in individuals with non-insulin-dependent diabetes mellitus. 2001 , 41, 600-11	47
810	[Some considerations on the Consensus of the Spanish Diabetes Society and the Spanish Society of Family and Community Medicine on the criteria and guidelines for combined therapy for type 2 diabetes]. 2001 , 28, 624-5	
809	Algunas consideraciones sobre el Consenso de la Sociedad Española de Diabetes y de la Sociedad Española de Medicina Familiar y Comunitaria sobre los criterios y pautas de terapia combinada en la diabetes tipo 2. 2001 , 48, 220-221	
808	[The COMBO project. Criteria and guidelines for combined therapy of type 2 diabetes. Consensus document (and II)]. 2001 , 27, 351-63	
807	Management of Diabetes Mellitus. 2001 , 9, 711-730	2
806	Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. 2001 , 111, 10-7	207
805	The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus. 2001 , 111, 633-42	127
804	Type 2 diabetes in children and adolescents: an emerging disease. 2001 , 15, 187-93	7
803	Metformin-associated lactic acidosis. 2001 , 20, 267-72	39
802	Diabetes mellitus and coronary heart disease. 2001 , 30, 857-81	36
801	[The COMBO project. Criteria and guidelines for the combined treatment of type 2 diabetes. Consensus document (I)]. 2001 , 27, 197-206	0

800	Glycogen phosphorylase inhibitors for treatment of type 2 diabetes mellitus. 2001 , 10, 439-54	219
799	Criterios y pautas de terapia combinada en la diabetes tipo 2. 2001 , 48, 82-97	5
798	The Importance of Individualized Pharmaceutical Therapy in the Treatment of Diabetes Mellitus. 2001 , 4, 5-23	6
797	The effect of chronic exposure to fatty acids on gene expression in clonal insulin-producing cells: studies using high density oligonucleotide microarray. 2001 , 142, 4777-84	52
796	Quinapril treatment enhances vascular sensitivity to insulin. 2001 , 19, 113-8	13
795	The Genetics of Type 2 Diabetes. 2001 , 11, 178-187	15
794	Perioperative Care of the Diabetic Patient. 2001 , 29, 1-9	9
793	Inevitability of beta cell failure in type 2 diabetes. 2001 , 8, 192-196	
792	The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. 2001 , 107, E55	294
791	Insulin, glucagon, and hypoglycemic drugs. 2001 , 24, 487-502	
790	Metformin for type 2 diabetes mellitus. 2001 ,	
789	Cardiovascular Risk Management in Type 2 Diabetes: From Clinical Trials to Clinical Practice. 2001 , 11, 474-490	5
788	Management of the insulin resistance syndrome. 2001 , 1, 140-7	12
787	Combating diabetic nephropathy with drug therapy. 2001 , 1, 148-56	11
786	Nephropathy in type 2 diabetes: current therapeutic strategies. 2001 , 6, 266-269	2
785	From symptomatic treatments to causative therapy?. 2001 , 5, 352-9	3
784	Emerging therapies in type 2 diabetes. 2001 , 18, S16-S18	
783	Enzyme specificity and tissue distribution of zenarestat, an aldose reductase inhibitor, and its relevance in the use of zenarestat as a therapeutic agent against diabetic neuropathy. 2001 , 54, 27-34	3

782	Myositis, microvesicular hepatitis, and progression to cirrhosis from troglitazone added to simvastatin. 2001 , 46, 376-8	16
781	Oral agents for the treatment of type 2 diabetes mellitus: pharmacology, toxicity, and treatment. 2001 , 38, 68-78	100
780	Metabolism. Controlling the glucose factory. 2001 , 413, 125-6	32
779	Insulin therapy: optimizing control in type 1 and type 2 diabetes. 2001 , 4, 50-64	17
778	Metformin as a cause of late-onset chronic diarrhea. 2001 , 21, 1422-4	27
777	Assessment of hepatic insulin action in obese type 2 diabetic patients. 2001 , 50, 1363-70	65
776	Increased uncoupling protein-2 levels in beta-cells are associated with impaired glucose-stimulated insulin secretion: mechanism of action. 2001 , 50, 1302-10	289
775	Recent Developments in the Pharmacological Reduction of Blood Glucose in Patients With Type 2 Diabetes. 2001 , 19, 153-159	5
774	Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. 2001 , 24, 710-9	335
773	Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes. 2001 , 24, 720-5	65
772	A novel small molecule that directly sensitizes the insulin receptor in vitro and in vivo. 2001 , 50, 824-30	60
771	The clinical importance of postprandial hyperglycemia. 2001 , 27, 624-6, 632-4, 636-7	3
770	Postchallenge hyperglycemia in a national sample of U.S. adults with type 2 diabetes. 2001 , 24, 1734-8	72
769	Konjac-Mannan and American ginseng: emerging alternative therapies for type 2 diabetes mellitus. 2001 , 20, 370S-380S; discussion 381S-383S	102
768	A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. 2001 , 96, 519-25	291
767	Lipids and diabetes mellitus: a review of therapeutic options. 2002 , 18 Suppl 1, s58-74	3
766	Orlistat in the treatment of Type 2 diabetes mellitus. 2002 , 3, 599-605	8
765	Nucleotide sensitivity of pancreatic ATP-sensitive potassium channels and type 2 diabetes. 2002 , 51 Suppl 3, S358-62	37

764	Effects of American ginseng berry extract on blood glucose levels in ob/ob mice. 2002 , 30, 187-94	60
763	Type 2 diabetes mellitus in children and youth: a new epidemic. 2002 , 15 Suppl 2, 737-44	125
762	Effect of combination glipizide GITS/metformin on fibrinolytic and metabolic parameters in poorly controlled type 2 diabetic subjects. 2002 , 25, 2123-8	43
761	On combination therapy of diabetes with metformin and dipeptidyl peptidase IV inhibitors. 2002 , 25, 1490-1; author reply 1491-2	10
760	Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects. 2002 , 51, 30-6	92
759	Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. 2002 , 25, 2244-8	334
758	HbA(1c) and glycemic profile, basal- and post-treatment with Miglitol, in an area with a Mediterranean diet. 2002 , 25, 1896-8	2
757	Plasma lipids and antidiabetic agents: a brief overview. 2002 , 2, 40-43	10
756	Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial. 2002 , 25, 1033-41	246
755	Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. 2002 , 25, 1123-8	214
754	Discovery of small molecule insulin mimetics as potential novel antidiabetic agents. 2002 , 227-236	
753	Treatment of type 2 diabetes mellitus: pharmacologic intervention. 2002 , 16, 55-67	7
752	Current oral agents for type 2 diabetes. Many options, but which to choose when?. 2002 , 111, 32-4, 37-40, 43-6	14
751	New pharmacological tools for obesity. 2002 , 25, 905-14	2
750	Pharmacokinetics and pharmacodynamics of extended-release glipizide GITS compared with immediate-release glipizide in patients with type II diabetes mellitus. 2002 , 42, 651-7	22
749	Small steps, large problems: advances in the management of diabetes mellitus. 2002 , 113, 339-40	4
748	Evaluation of alternative strategies for optimizing glycemia: progress to date. 2002 , 113 Suppl 6A, 23S-35S	24
747	Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1. 2002 , 291, 1302-8	103

746	Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus. 2002 , 62, 1805-37	126
745	Novedades en el tratamiento con antidiabéticos orales. 2002 , 9, 471-480	
744	Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. 2002 , 346, 393-403	13212
743	Antidiabetic effects of Panax ginseng berry extract and the identification of an effective component. 2002 , 51, 1851-8	466
742	New solutions for type 2 diabetes mellitus: the role of pioglitazone. 2002 , 20 Suppl 1, 1-9	13
741	Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second beta-cell hormone. 2002 , 4, 175-89	62
740	Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of type 2 diabetes mellitus. 2002 , 24, 1690-705	11
739	Diabetes mellitus. 2002 , 19, 79-107	34
738	[Treatment of diabetes mellitus: general goals, and clinical practice management]. 2002 , 55, 845-60	19
737	Thiazolidinediones and type 2 diabetes: new drugs for an old disease. 2002 , 176, 381-6	48
736	Long-term efficacy of triple oral therapy for type 2 diabetes mellitus. 2002 , 8, 271-5	42
735	Metabolic Homeostasis. 2002 , 485-519	2
734	Effect of thiazolidinediones on high-density lipoprotein subfractions. 2002 , 8, 102-4	11
733	Risk of acute liver injury in patients with diabetes. 2002 , 22, 1091-6	14
732	Effects of S 21403 on hormone secretion from isolated rat pancreas at different glucose concentrations. 2002 , 456, 141-7	5
731	Reappraisal of the pharmacologic approach to treatment of type 2 diabetes mellitus. 2002 , 90, 42G-50G	140
730	Troglitazone: the discovery and development of a novel therapy for the treatment of Type 2 diabetes mellitus. 2002 , 54, 1173-97	55
729	Abstracts of the 6th International Congress of the Immunology of Diabetes Society and American Diabetes Association Research Symposium. October 3-6, 2002, Copper Mountain, Colorado, USA. 2002 , 18 Suppl 4, S1-45	18

728	Oral combination therapy for type 2 diabetes. 2002 , 18 Suppl 3, S70-6	44
727	Challenges in optimal metabolic control of diabetes. 2002 , 18 Suppl 3, S36-41	22
726	Insulin resistance, diabetes, and atherosclerosis: thiazolidinediones as therapeutic interventions. 2002 , 4, 514-21	27
725	Structure-activity analysis of the purine binding site of human liver glycogen phosphorylase. 2002 , 9, 915-24	34
724	Approaches to preventing mealtime hyperglycaemic excursions. 2002 , 4, 11-8	2
723	Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients. 2002 , 4, 177-86	52
722	Effect of misoprostol (PGE1) on glucose metabolism in type-2-diabetic and control subjects. 2002 , 4, 195-200	2
721	Rosiglitazone amplifies the benefits of lifestyle intervention measures in long-standing type 2 diabetes mellitus. 2002 , 4, 270-5	36
720	Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. 2002 , 4, 201-8	96
719	Glyburide/metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulphonylurea therapy. 2002 , 4, 368-75	48
718	Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance) in Type 2 diabetic patients inadequately controlled on metformin. 2002 , 19, 673-80	67
717	Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. 2002 , 19, 708-23	821
716	Small molecule insulin mimetics reduce food intake and body weight and prevent development of obesity. 2002 , 8, 179-83	141
715	Clinical pharmacology physiology conference: metformin and lactic acidosis (LA). 2002 , 34, 419-23	3
714	Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. 2003 , 37, 1202-19	1468
713	Type 2 diabetes in children and youth. 2003 , 4, 33-42	22
712	Archimedes: a trial-validated model of diabetes. 2003 , 26, 3093-101	197
711	Antidiabetic effect of chronic administration of JTT-608, a new hypoglycemic agent, in diabetic Goto-Kakizaki rats. 2003 , 476, 159-66	10

710	Influence of initial hyperglycaemia, weight and age on the blood glucose lowering efficacy and incidence of hypoglycaemic symptoms with a single-tablet metformin-glibenclamide therapy (Glucovance) in type 2 diabetes. 2003 , 5, 171-9	17
709	Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets. 2003 , 5, 408-14	51
708	Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co-administered with metformin. 2003 , 5, 424-31	56
707	Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation. 2003 , 55, 147-57	46
706	Prevention of type 2 diabetes in youth: etiology, promising interventions and recommendations. 2003 , 4, 174-209	14
705	Pharmacological management of type 2 diabetes mellitus: rationale for rational use of insulin. 2003 , 78, 459-67	50
704	Tiazolidinadionas: efecto de la pioglitazona sobre la hiperglucemia, la dislipidemia y el riesgo cardiovascular. 2003 , 203, 33-40	
703	Insulin sensitizers. 2003 , 78, 471-9	26
702	The management of the obese diabetic patient. 2003 , 30, 465-91	42
701	Diabetes mellitus and pharmacological therapy. 2003 , 20, 635-53	
700	Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. 2002 , CD002967	48
699	The importance of insulin resistance in polycystic ovary syndrome. 2003 , 80, 255-8	73
698	Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus?. 2003 , 63, 933-51	157
697	Current management strategies for coexisting diabetes mellitus and obesity. 2003 , 63, 1165-84	65
696	Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. 2003 , 63, 1373-405	217
695	Metformin: new understandings, new uses. 2003 , 63, 1879-94	233
694	PTP1B inhibitors as potential therapeutics in the treatment of type 2 diabetes and obesity. 2003 , 12, 223-33	188
693	Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis. 2003 , 52, 1638-42	49

692	Clinical use of thiazolidinediones: recommendations. 2003 , 115 Suppl 8A, 116S-120S	9
691	Effect of thiazolidinediones on body weight in patients with diabetes mellitus. 2003 , 115 Suppl 8A, 42S-48S	228
690	Efficient syntheses of benzothiazepines as antagonists for the mitochondrial sodium-calcium exchanger: potential therapeutics for type II diabetes. 2003 , 68, 92-103	41
689	Relative impact of insulin resistance and obesity on cardiovascular risk factors in polycystic ovary syndrome. 2003 , 52, 713-9	30
688	Mode of action of ipomoea batatas (Caiapo) in type 2 diabetic patients. 2003 , 52, 875-80	63
687	Combination treatment with metformin and glibenclamide versus single-drug therapies in type 2 diabetes mellitus: a randomized, double-blind, comparative study. 2003 , 52, 862-7	36
686	Insulin therapy in type 2 diabetes. 2003 , 49, 377-420	11
685	Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea. 2003 , 25, 890-903	43
684	New developments in type 2 diabetes mellitus: combination therapy with a thiazolidinedione. 2003 , 25, 1895-917	13
683	Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy. 2003 , 25, 3109-23	19
682	Regulation of skeletal muscle morphology in type 2 diabetic subjects by troglitazone and metformin: relationship to glucose disposal. 2003 , 52, 540-6	40
681	Mitochondrial metabolism and type-2 diabetes: a specific target of metformin. 2003 , 29, 6S88-94	95
680	Meglitinide analogues for type 2 diabetes mellitus. 2003 ,	4
679	Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity. 2003 , 2, 33-47	92
678	Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. 2003 , 22, 331-9	322
677	Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus. 2003 , 21, 501-12	30
676	Pramlintide for the treatment of diabetes mellitus. 2003 , 37, 1082-9	26
675	Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. 2003 , 88, 3598-604	82

674	Clarifying the Role of Insulin in Type 2 Diabetes Management. 2003 , 21, 14-21	12
673	The diabetes prevention program and its global implications. 2003 , 14, S103-7	36
672	Pharmacological agents that directly modulate insulin secretion. 2003 , 55, 105-31	193
671	The development of an oral antidiabetic combination tablet: design, evaluation and clinical benefits for patients with type 2 diabetes. 2003 , 19, 218-25	13
670	Update on diabetes diagnosis and management. 2003 , 134 Spec No, 16S-23S	7
669	Recent antihyperglycemic prescribing trends for US privately insured patients with type 2 diabetes. 2003 , 26, 1847-51	90
668	Inhibition of net HepG2 cell apolipoprotein B secretion by the citrus flavonoid naringenin involves activation of phosphatidylinositol 3-kinase, independent of insulin receptor substrate-1 phosphorylation. 2003 , 52, 2554-61	116
667	Metaphosphate in the active site of fructose-1,6-bisphosphatase. 2003 , 278, 16015-20	26
666	Treatment of type 2 diabetes. 2003 , 58, 318-24	13
665	Occult Cushing [®] syndrome in type-2 diabetes. 2003 , 88, 5808-13	219
664	Pharmacotherapy of diabetes mellitus: implications for the prevention and treatment of cardiovascular disease. 2003 , 5, 18-33	4
663	Trends in Management of Type 2 Diabetes. 2003 , 13, S1-S21	2
662	What is the role for insulin therapy in type 2 diabetes?. 2003 , 10, 99-103	4
661	Metformin for the Treatment of Polycystic Ovary Syndrome. 2003 , 101, 785-793	18
660	Peripheral Arterial Disease. 2003 , 561-571	1
659	A practical scheme for the initial out-patient management of type-2 diabetes mellitus. 2003 , 33, 14-8	
658	Pharmaceutical add,on therapies for patients with type 2 diabetes. 2003 , 1, 176-179	
657	DIABETES MELLITUS Treatment and Management. 2003 , 1787-1794	1

656	Glicemia p̄-prandial. 2003 , 47, 728-738	4
655	Practical office strategies for weight management of the obese diabetic individual. 2004 , 10, 153-9	10
654	Substitution of pioglitazone for troglitazone in patients with type 2 diabetes. 2004 , 10, 18-23	4
653	Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. 2004 , 89, 200-6	305
652	Durability of glycemic control: a feature of the thiazolidinediones. 2004 , 6, 179-89	4
651	Rosiglitazone plus metformin: combination therapy for Type 2 diabetes. 2004 , 5, 1411-22	12
650	The Role of the Optimal Healing Environment in the Care of Patients with Diabetes Mellitus Type II. 2004 , 10, S-223-S-229	3
649	Improved glycemic control without weight gain using triple therapy in type 2 diabetes. 2004 , 27, 1577-83	51
648	Insulin strategies for type 2 diabetes mellitus. 2004 , 38, 1916-23	6
647	Insulin sensitivity during oral glucose tolerance test and its relations to parameters of glucose metabolism and endothelial function in type 2 diabetic subjects under metformin and thiazolidinedione. 2004 , 060721083724027	
646	Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. 2004 , 53, 2397-403	220
645	Stimulation of hepatocyte glucose metabolism by novel small molecule glucokinase activators. 2004 , 53, 535-41	124
644	Efficacy of Ipomoea batatas (Caiapo) on diabetes control in type 2 diabetic subjects treated with diet. 2004 , 27, 436-40	58
643	Treatment of the patient with diabetes: importance of maintaining target HbA(1c) levels. 2004 , 20, 1919-27	38
642	Healthcare costs and prescription adherence with introduction of thiazolidinedione therapy in Medicaid type 2 diabetic patients: a retrospective data analysis. 2004 , 20, 1633-40	19
641	Oral Antidiabetic Agents: A Comparative Review. 2004 , 17, 39-48	11
640	Effects of short-term metformin treatment on insulin sensitivity of blood glucose and free fatty acids. 2004 , 6, 8-15	15
639	Glucagon-like peptide: the time is near. 2004 , 95, 249-51	2

638	Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients. 2004 , 28, 783-9	118
637	The first crystal structure of the novel class of fructose-1,6-bisphosphatase present in thermophilic archaea. 2004 , 12, 949-59	31
636	Hypoglycemia as a barrier to glycemic control. 2004 , 18, 60-8	107
635	Anti-hyperglycemic effect of the polysaccharides fraction from American ginseng berry extract in ob/ob mice. 2004 , 11, 182-7	64
634	Sulfonylurea treatment of type 2 diabetes mellitus: focus on glimepiride. 2004 , 24, 606-20	46
633	The utility of insulin glargine in the treatment of diabetes mellitus. 2004 , 24, 736-42	5
632	The effect of deinsuring chlorpropamide on the prescribing of oral antihyperglycemics for Nova Scotia SeniorsPharmacare beneficiaries. 2004 , 24, 784-91	6
631	Biochemical and morphological effects of K-111, a peroxisome proliferator-activated receptor (PPAR)alpha activator, in non-human primates. 2004 , 68, 239-51	30
630	Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. 2004 , 27, 2628-35	1088
629	Metformin and lactic acidosis: cause or coincidence? A review of case reports. 2004 , 255, 179-87	142
628	Compared to glibenclamide, repaglinide treatment results in a more rapid fall in glucose level and beta-cell secretion after glucose stimulation. 2004 , 20, 466-71	10
627	Design and acceptability of patient-oriented computerized diabetes care reminders for use at the point of care. 2004 , 29, 157-68	7
626	Impaired glucose metabolism in patients with heart failure: pathophysiology and possible treatment strategies. 2004 , 4, 269-80	28
625	Translating lifestyle intervention to practice in obese patients with type 2 diabetes: Improving Control with Activity and Nutrition (ICAN) study. 2004 , 27, 1570-6	187
624	Acanthosis nigricans associated with insulin resistance : pathophysiology and management. 2004 , 5, 199-203	96
623	[Criteria and guidelines for combined therapy of type 2 diabetes. 2004 consensus document]. 2004 , 123, 187-97	3
622	Mechanisms and therapeutic targets in type 2 diabetes mellitus. 2004 , 1, 151-157	26
621	Diabetes mellitus: pathogenesis and treatment strategies. 2004 , 47, 4113-7	155

620	Pioglitazone as monotherapy or in combination with sulfonylurea or metformin enhances insulin sensitivity (HOMA-S or QUICKI) in patients with type 2 diabetes. 2004 , 20, 723-8	19
619	Emerging aspects of pharmacotherapy for obesity and metabolic syndrome. 2004 , 50, 453-69	38
618	Combined thiazolidinedione-insulin therapy: should we be concerned about safety?. 2004 , 27, 841-56	48
617	Evolving strategies for insulin delivery and therapy. 2004 , 64, 1149-61	20
616	Pramlintide for the treatment of insulin-requiring diabetes mellitus: rationale and review of clinical data. 2004 , 64, 1419-32	54
615	Pioglitazone is effective therapy for elderly patients with type 2 diabetes mellitus. 2004 , 21, 259-71	24
614	Practical considerations and guidelines for dosing sulfonylureas as monotherapy or combination therapy. 2004 , 26, 1714-27	39
613	Type II Diabetes Mellitus and impaired glucose tolerance in Yemen: prevalence, associated metabolic changes and risk factors. 2004 , 65, 275-81	30
612	Treatment satisfaction after commencement of insulin in Type 2 diabetes. 2004 , 66, 263-7	25
611	Weight gain during insulin therapy in patients with type 2 diabetes mellitus. 2004 , 65 Suppl 1, S23-7	80
610	Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial. 2004 , 116, 223-9	84
609	Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial. 2004 , 116, 230-5	82
608	Evaluation of the Oral Antihyperglycemic Drug Metformin in Normal and Diabetic Cats. 2004 , 18, 18-24	22
607	Progress with thiazolidinediones in the management of type 2 diabetes mellitus. 2004 , 26, 177-90	52
606	New strategies for basal insulin treatment in type 2 diabetes mellitus. 2004 , 26, 889-901	27
605	Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. 2004 , 239, 1-11	490
604	6-(β -Hydroxy- β -aryl/naphthyl)methyl-3,4-dihydro-2,5-benzodiazocin-1(2H)-ones and diphenylmethanes from C-2 arylated 1,3-indanediones. 2004 , 2004, 781-783	9
603	Type 2 diabetes: treat to target. 2004 , 29, 11-5, 19-23; quiz 23-5	13

602	Metformin inhibits mitochondrial permeability transition and cell death: a pharmacological in vitro study. 2004 , 382, 877-84	122
601	Addition of rosiglitazone to glimepirid and metformin combination therapy in type 2 diabetes. 2004 , 51, 521-7	18
600	Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on glucose-stimulated insulin secretion. 2004 , 286, E1023-31	127
599	Microsomal triglyceride transfer protein gene expression and ApoB secretion are inhibited by bitter melon in HepG2 cells. 2005 , 135, 702-6	31
598	Effect of whey on blood glucose and insulin responses to composite breakfast and lunch meals in type 2 diabetic subjects. 2005 , 82, 69-75	249
597	Effect of increased cost-sharing on oral hypoglycemic use in five managed care organizations: how much is too much?. 2005 , 43, 951-9	69
596	Introduction to the Kinases in Diabetes Biochemical Society Focused Meeting: are protein kinases good targets for antidiabetic drugs?. 2005 , 33, 339-42	4
595	Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects. 2005 , 45, 570-7	64
594	Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus. 2005 , 7, 633-41	30
593	Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones. 2005 , 7, 675-91	92
592	Evaluation of drug therapy and risk factors in diabetic hypertensives: a study of the quality of care provided in diabetic clinics in Bahrain. 2005 , 11, 121-31	7
591	Inhibition of cellular responses to insulin in a rat liver cell line. A role for PKC in insulin resistance. 2005 , 563, 471-82	9
590	Improving glucose management: ten steps to get more patients with type 2 diabetes to glycaemic goal. 2005 , 59, 1345-55	97
589	Antihyperglycemic effects of total ginsenosides from leaves and stem of Panax ginseng. 2005 , 26, 1104-10	64
588	Development of a glyburide-metformin fixed combination tablet with optimized glyburide particle size. 2005 , 66, 25-35	1
587	Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. 2005 , 21, 167-74	132
586	The impact of antidiabetic therapies on cardiovascular disease. 2005 , 7, 50-7	16
585	Prostate cancer risk among men with diabetes mellitus (Spain). 2005 , 16, 1055-8	44

584	Effect of whey on blood glucose and insulin responses to composite breakfast and lunch meals in type 2 diabetic subjects. 2005 , 82, 69-75	240
583	Initiating basal insulin therapy in patients with type 2 diabetes mellitus. 2005 , 62, 510-8	5
582	Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. 2005 , 62, 173-81	316
581	Predictors of improved glycaemic control with rosiglitazone therapy in type 2 diabetic patients: a practical approach for the primary care physician. 2005 , 5, 28-35	13
580	Exenatide: A Novel Therapeutic Approach for Type 2 Diabetes Mellitus. 2005 , 21, 191-196	
579	Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. 2005 , 28, 1083-91	1034
578	Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. 2005 , 28, 1092-100	1231
577	Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. 2005 , 54, 1150-6	384
576	Nonalcoholic Fatty Liver (NAFL): Overview. 2005 , 1-43	
575	Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes. 2005 , 28, 266-72	55
574	Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. 2005 , 28, 2948-61	322
573	Description and preliminary evaluation of a Multiagent Intelligent Dosing System (MAIDS) to manage combination insulin-oral agent therapy in type 2 diabetes. 2005 , 7, 937-47	3
572	The effect of rosiglitazone on overweight subjects with type 1 diabetes. 2005 , 28, 1562-7	41
571	Caring for poorly controlled diabetes mellitus: a randomized pharmacist intervention. 2005 , 39, 433-40	97
570	Diabetes in African Americans. 2005 , 81, 734-40	88
569	Metformin monotherapy for type 2 diabetes mellitus. 2005 , CD002966	156
568	Oral agents in managing diabetes mellitus in children and adolescents. 2005 , 52, 1689-703	3
567	Type 2 diabetes in children and youth. 2005 , 34, 659-76, ix-x	35

566	Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinations. 2005 , 34, 77-98	76
565	Weight gain in type 2 diabetics with different treatment modalities. 2005 , 3, 130-6	3
564	Type 2 diabetes mellitus in children and adolescents. 2005 , 28, 853-63	37
563	Targeting vascular risk in patients with metabolic syndrome but without diabetes. 2005 , 54, 1065-74	56
562	Making improvements in the management of patients with type 2 diabetes: a possible role for the control of variation in glycated hemoglobin. 2005 , 64, 792-801	
561	Anti-diabetic effect of ginsenoside Re in ob/ob mice. 2005 , 1740, 319-25	117
560	Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study. 2005 , 27, 1548-61	62
559	Early use of insulin in type 2 diabetes. 2005 , 68 Suppl1, S30-5	11
558	Comparison of the quality of diabetes care in primary care diabetic clinics and general practice clinics. 2005 , 70, 174-82	16
557	Future alternative therapies in a quest to halt aberrations in diabetes mellitus. <i>Biomedicine and Pharmacotherapy</i> , 2005 , 59, 296-301	7.5 8
556	Protease inhibitor-induced diabetic complications : incidence, management and prevention. 2005 , 28, 209-26	4
555	Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. 2005 , 44, 1209-25	149
554	Oral antidiabetic agents: current role in type 2 diabetes mellitus. 2005 , 65, 385-411	828
553	Gliclazide modified release. 2005 , 65, 1449-50	2
552	Risk factors for atherosclerotic vascular disease. 2005 , 71-105	18
551	Thiazolidinediones for the therapeutic management of polycystic ovary syndrome : impact on metabolic and reproductive abnormalities. 2006 , 5, 171-87	14
550	Practical review of oral antihyperglycemic agents for type 2 diabetes mellitus. 2006 , 32, 869-76	22
549	Glycemic control in the metabolic syndrome and implications in preventing cardiovascular disease. 2006 , 4, 315-27	3

548	A dual PPAR alpha/gamma agonist increases adiponectin and improves plasma lipid profiles in healthy subjects. 2006 , 7, 99-110	15
547	Gliquidone contributes to improvement of type 2 diabetes mellitus management: a review of pharmacokinetic and clinical trial data. 2006 , 7, 331-7	19
546	Outcomes associated with introduction of thiazolidinedione therapy in Medicaid enrolled patients with type 2 diabetes: an updated and expanded retrospective analysis. 2006 , 22, 551-9	7
545	Type 2 diabetes in children and adolescents--the next epidemic?. 2006 , 22, 297-306	68
544	Benefits of early initiation of insulin therapy to long-term goals in type 2 diabetes mellitus. 2006 , 1, 2-12	3
543	Tight control of hyperglycemia in type 2 diabetes mellitus. 2006 , 1, 166-172	8
542	Effects of glimepiride and glyburide on glucose counterregulation and recovery from hypoglycemia. 2006 , 55, 78-83	35
541	Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form. 2006 , 22, 1879-92	145
540	Pharmacologic interventions for type 1 and type 2 diabetes. 2006 , 41, 589-604, vii	
539	The application of evidence-based principles of care in older persons (issue 3): management of diabetes mellitus. 2006 , 7, 234-40	29
538	Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial. 2006 , 22, 751-9	61
537	Effect of inhibition of alpha-glucosidase on age-related glucose intolerance and pancreatic atrophy in rats. 2006 , 55, 533-40	32
536	Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. 2006 , CD002967	81
535	[Metformin-associated lactic acidosis]. 2006 , 25, 1046-52	13
534	Effects of gliclazide dose escalation on postprandial hyperglycemia in type 2 diabetes mellitus: A prospective, open-label, case-controlled, dose-escalation study. 2006 , 67, 81-102	4
533	Biochemical mechanism of insulin sensitization, lipid modulation and anti-atherogenic potential of PPAR alpha/gamma dual agonist: Ragaglitazar. 2006 , 80, 235-44	8
532	Effects of okchun-san, a herbal formulation, on blood glucose levels and body weight in a model of Type 2 diabetes. 2006 , 103, 491-5	31
531	Reducing cardiovascular risk in diabetes: beyond glycemic and blood pressure control. 2006 , 110, 137-45	15

530	Spontaneous motor activity in fat-fed, streptozotocin-treated rats: a nonobese model of type 2 diabetes. 2006 , 87, 765-72	12
529	Comparison of the Efficacy and Safety of Glimepiride/Metformin Fixed Combination Versus Free Combination in Patients with Type 2 Diabetes: Multicenter, Randomized, Controlled Trial. 2006 , 30, 466	2
528	Bariatric surgery: effects on glucose homeostasis. 2006 , 9, 497-507	80
527	Oxidative stress in type 2 diabetes: the role of fasting and postprandial glycaemia. 2006 , 60, 308-14	324
526	Pioglitazone and reductions in post-challenge glucose levels in patients with type 2 diabetes. 2006 , 8, 31-8	8
525	Insulin sensitivity during oral glucose tolerance test and its relations to parameters of glucose metabolism and endothelial function in type 2 diabetic subjects under metformin and thiazolidinedione. 2006 , 8, 561-7	16
524	Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. 2006 , 8, 156-63	46
523	Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. 2006 , 8, 419-28	180
522	Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. 2006 , 8, 436-47	360
521	The effect of obesity on glycaemic response to metformin or sulphonylureas in Type 2 diabetes. 2006 , 23, 128-33	63
520	Effect of metformin plus rosiglitazone compared with metformin alone on glycaemic control in well-controlled Type 2 diabetes. 2006 , 23, 1069-78	27
519	Increased sensitivity of glycogen synthesis to phosphorylase-a and impaired expression of the glycogen-targeting protein R6 in hepatocytes from insulin-resistant Zucker fa/fa rats. 2006 , 273, 1989-99	5
518	Lifestyle intervention in obese patients with type 2 diabetes: impact of the patient's educational background. 2006 , 14, 1085-92	22
517	Sulphonylureas. 2006 , 3230-3242	
516	The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. 2006 , 244, 741-9	670
515	A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus. 2006 , 33, 313-43	109
514	Are sulphonylureas pass?. 2006 , 6, 373-7	20
513	Management of diabetes mellitus in older persons. 2006 , 27, 77-82	5

512	The effect of the ingestion of Ginkgo biloba extract (EGb 761) on the pharmacokinetics of metformin in non-diabetic and type 2 diabetic subjects--a double blind placebo-controlled, crossover study. 2006 , 25, 606-16	38
511	Management of type 2 diabetes: the role of incretin mimetics. 2006 , 67, 545-552	1
510	Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. 2006 , 22, 483-91	89
509	Management of Type 2 diabetes: the role of incretin mimetics. 2006 , 7, 2095-105	24
508	New insights into glucose regulation. 2006 , 32, 221-8	16
507	AMPK activation restores the stimulation of glucose uptake in an in vitro model of insulin-resistant cardiomyocytes via the activation of protein kinase B. 2006 , 291, H239-50	109
506	Treatment Algorithms and the Pharmacological Management of Type 2 Diabetes. 2006 , 19, 249-255	4
505	Intrinsic gluconeogenesis is enhanced in renal proximal tubules of Zucker diabetic fatty rats. 2006 , 17, 398-405	47
504	Trends in the prescribing of oral agents for the management of type 2 diabetes mellitus in the United States, 1990-2001: does type of insurance influence access to innovation?. 2006 , 32, 940-53	7
503	Type 2 diabetes-an introduction to the development and use of animal models. 2006 , 47, 181-5	22
502	Incretin mimetics and dipeptidyl peptidase-IV inhibitors: a review of emerging therapies for type 2 diabetes. 2006 , 8, 385-96	39
501	Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. 2006 , 55, 1695-704	395
500	The metabolic syndrome: recognition and management. 2006 , 9, 16-33	13
499	Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea. 2006 , 29, 2371-7	23
498	Exenatide: first-in-class incretin mimetic for the treatment of Type 2 diabetes mellitus. 2006 , 1, 329-341	18
497	Predictors of metabolic control at one year in a population of pediatric patients with type 2 diabetes mellitus: a retrospective study. 2006 , 19, 1141-9	2
496	Pharmacological studies on anti-hyperglycemic effect of folium eribotryae. 2007 , 35, 705-11	26
495	Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin. 2007 , 30, 2794-9	91

494	The role of vildagliptin in the management of type 2 diabetes mellitus. 2007 , 41, 824-32	21
493	Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study. 2007 , 21, 625-32	43
492	Supratherapeutic doses of sulfonylureas in diabetic patients: how much is too much?. 2007 , 45, 482-4	1
491	Factors associated with diabetes onset during metformin versus placebo therapy in the diabetes prevention program. 2007 , 56, 1153-9	66
490	Clinical research observations with use of exubera in patients with type 1 and 2 diabetes. 2007 , 9 Suppl 1, S28-40	5
489	Insulin therapy in type 2 diabetes. 2007 , 32, 71-107	5
488	Dose-response relationships of sulfonylureas: will doubling the dose double the response?. 2007 , 100, 1132-6	7
487	Anti-diabetic effects of compound K versus metformin versus compound K-metformin combination therapy in diabetic db/db mice. 2007 , 30, 2196-200	62
486	Effects of Oral Administration of Moringa oleifera Lam on Glucose Tolerance in Goto-Kakizaki and Wistar Rats. 2007 , 40, 229-33	87
485	Combination therapy with new targets in Type 2 diabetes: a review of available agents with a focus on pre-exercise adjustment. 2007 , 27, 193-201	10
484	Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. 2007 , 29, 139-53	235
483	Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapy. 2007 , 29, 1236-53	36
482	Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis. 2007 , 29, 1294-305	94
481	Effect of pioglitazone therapy in lean type 1 diabetes mellitus. 2007 , 78, 349-54	34
480	Inhibitory potential of herb, fruit, and fungal-enriched cheese against key enzymes linked to type 2 diabetes and hypertension. 2007 , 8, 46-54	306
479	The hepatic PP1 glycogen-targeting subunit interaction with phosphorylase a can be blocked by C-terminal tyrosine deletion or an indole drug. 2007 , 581, 4749-53	25
478	[Treatment of type 2 diabetes: revision of current therapeutical options and priorities]. 2007 , 129, 746-57	
477	The Use of Premixed Insulin Analogues in the Treatment of Patients with Type 2 Diabetes Mellitus: Advantages and Limitations. 2007 , 2, 68-79	7

476	Effect of glyburide-metformin combination tablet in patients with type 2 diabetes. 2007 , 70, 473-80	13
475	Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. 2007 , 30, 1127-42	136
474	Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. 2007 , 320, 323-30	226
473	Effects of pioglitazone in combination with metformin or a sulfonylurea compared to a fixed-dose combination of metformin and glibenclamide in patients with type 2 diabetes. 2007 , 9, 387-98	13
472	Pramlintide acetate in the treatment of Type 2 and Type 1 diabetes mellitus. 2007 , 2, 9-18	2
471	Meglitinide analogues for type 2 diabetes mellitus. 2007 , CD004654	52
470	Diabetes: the latest trends in glycemic control. 2007 , 24, 159-89	2
469	A qualitative review of the role of qigong in the management of diabetes. 2007 , 13, 427-33	37
468	Oral anti-hyperglycemic agents for the management of gestational diabetes mellitus. 2007 , 34, 255-74, ix	13
467	The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes. 2007 , 9, 317-26	29
466	The role of different types of health insurance on access and utilization: comparative results on two chronic conditions (hypertension and diabetes type II without complication). 2007 , 28, 503-507	2
465	Liquid chromatography tandem mass spectrometry method for simultaneous determination of antidiabetic drugs metformin and glyburide in human plasma. 2007 , 45, 97-106	81
464	Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in Type II diabetes mellitus. 2007 , 82, 275-81	71
463	Pharmacotherapy for the treatment of patients with type 2 diabetes mellitus: rationale and specific agents. 2007 , 81, 636-49	35
462	American ginseng berry juice intake reduces blood glucose and body weight in ob/ob mice. 2007 , 72, S590-4	48
461	Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. 2007 , 9, 194-205	535
460	Dipeptidyl peptidase 4 inhibition and vildagliptin therapy for type 2 diabetes. 2007 , 61, 38-48	10
459	Mitochondria, ciglitazone and liver: a neglected interaction in biochemical pharmacology. 2007 , 567, 50-8	18

458	Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. 2007 , 99, 4i-20i	155
457	Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: a review of clinical studies. 2007 , 21, 196-204	26
456	Effect of pioglitazone and its combination with statins in coronary artery disease patients with hyperinsulinemia. 2007 , 85, 628-33	3
455	Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. 2007 , 50, 1723-31	107
454	Adherence to anti-diabetic drug therapy and self management practices among type-2 diabetics in Nigeria. 2008 , 30, 876-83	67
453	Exenatide as a treatment for diabetes and obesity: implications for cardiovascular risk reduction. 2008 , 10, 55-60	32
452	Effects of chronic hyperinsulinemia in insulin-resistant patients. 2008 , 8, 233-8	18
451	Time to insulin in type-2 diabetes: high hurdles or Santiago way?. 2008 , 45, 67-74	1
450	The antidiabetic activity of total lignan from Fructus Arctii against alloxan-induced diabetes in mice and rats. 2008 , 22, 97-101	32
449	Suboptimal glycaemic control in primary care: is the need for intensification of therapy recognised?. 2008 , 25, 269-272	2
448	Chromium picolinate and biotin combination improves glucose metabolism in treated, uncontrolled overweight to obese patients with type 2 diabetes. 2008 , 24, 41-51	88
447	Impact of therapeutic advances on hypoglycaemia in type 2 diabetes. 2008 , 24, 257-85	11
446	Synthesis of 5-chloro-N-aryl-1H-indole-2-carboxamide derivatives as inhibitors of human liver glycogen phosphorylase a. 2008 , 16, 5452-64	19
445	Synthesis and pharmacological evaluation of bis-3-(3,4-dichlorophenyl)acrylamide derivatives as glycogen phosphorylase inhibitors. 2008 , 16, 8627-34	6
444	Structural characterization and hypoglycemic activity of a polysaccharide isolated from the fruit of Physalis alkekengi L.. 2008 , 71, 316-323	71
443	Estimating the long-term cost-effectiveness of exenatide in the United States: an adjunctive treatment for type 2 diabetes mellitus. 2008 , 11, 22-33	31
442	Switch to oral hypoglycemic agent therapy from insulin injection in patients with type 2 diabetes. 2008 , 8, 218-26	5
441	Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients. 2008 , 10, 1204-11	61

440	Staged diabetes management according to individual patient insulin resistance and beta-cell function ameliorates glycaemic control in type 2 diabetes mellitus. 2008 , 69, 549-55	6
439	Hypoglycemic effects of a sesquiterpene glycoside isolated from leaves of loquat (<i>Eriobotrya japonica</i> (Thunb.) Lindl.). 2008 , 15, 98-102	64
438	The role of inhaled insulin in the treatment of type 2 diabetes. 2008 , 22, 420-9	5
437	Potential hypoglycemic effect of an ethanol extract of <i>Gynostemma pentaphyllum</i> in C57BL/KsJ-db/db mice. 2008 , 11, 709-16	55
436	Prevalence and antihyperglycemic prescribing trends for patients with type 2 diabetes in Italy: a 4-year retrospective study from national primary care data. 2008 , 57, 358-63	27
435	Pharmacokinetic/pharmacodynamic modelling in diabetes mellitus. 2008 , 47, 417-48	71
434	Pramlintide in the treatment of diabetes mellitus. 2008 , 22, 375-86	44
433	Metformina. 2008 , 55, 39-52	
432	Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. 2008 , 156, 623-32	72
431	Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. 2008 , 121, 149-157.e2	175
430	Eupatilin, isolated from <i>Artemisia princeps</i> Pampanini, enhances hepatic glucose metabolism and pancreatic beta-cell function in type 2 diabetic mice. 2008 , 82, 25-32	55
429	Antidiabéticos orales. 2008 , 10, 1188-1194	
428	Guía de utilización de antidiabéticos orales: criterios de inicio, seguimiento, combinación y sustitución. 2008 , 10, 1209-1212	
427	Oral diabetic medications and the geriatric patient. 2008 , 24, 541-9, viii	6
426	Saponins isolated from the root of <i>Panax notoginseng</i> showed significant anti-diabetic effects in KK-Ay mice. 2008 , 36, 939-51	60
425	Novel substituted aminoalkylguanidines as potential antihyperglycemic and food intake-reducing agents. 2008 , 51, 3073-6	15
424	Treatment of type 2 diabetes with combined therapy: what are the pros and cons?. 2008 , 31 Suppl 2, S131-5	23
423	Inhibition of the interaction between protein phosphatase 1 glycogen-targeting subunit and glycogen phosphorylase increases glycogen synthesis in primary rat hepatocytes. 2008 , 412, 359-66	21

422	Combined therapy with insulin plus oral agents: is there any advantage? An argument in favor. 2008 , 31 Suppl 2, S125-30	26
421	PPAR-gamma agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis. 2008 , 294, L891-901	149
420	Molecular recognition of the protein phosphatase 1 glycogen targeting subunit by glycogen phosphorylase. 2008 , 283, 8913-8	23
419	Management of new-onset diabetes mellitus after transplantation. 2008 , 120, 60-6	3
418	Mechanism of the inhibitory action of chestnut astringent skin extract on carbohydrate absorption. 2008 , 54, 416-21	6
417	Gastrointestinal surgery as treatment for type 2 diabetes. 2008 , 15, 153-8	37
416	Optimizing insulin therapy in patients with type 1 and type 2 diabetes mellitus: optimal dosing and timing in the outpatient setting. 2008 , 15, 543-50	5
415	Safety and efficacy of nateglinide/metformin combination therapy in the treatment of type 2 diabetes. 2008 , 4, 1167-78	7
414	New combination treatments in the management of diabetes: focus on sitagliptin-metformin. 2008 , 4, 743-51	33
413	Metformin and lactic acidosis in an Australian community setting: the Fremantle Diabetes Study. 2008 , 188, 446-9	50
412	Bariatric Surgery as a Treatment for Type 2 Diabetes Mellitus in Obese Patients. 2009 , 5, 112-118	
411	The effects of a computer-tailored message on secondary prevention in type 2 diabetes: a randomized trial. 2009 , 12, 197-204	5
410	Incretin-based therapies: viewpoints on the way to consensus. 2009 , 32 Suppl 2, S223-31	123
409	Defining the importance of daily glycemic control and implications for type 2 diabetes management. 2009 , 121, 82-93	11
408	Novel Approaches to the Treatment of Type 2 Diabetes. 2009 , 22, 320-332	3
407	SirT1 knockdown in liver decreases basal hepatic glucose production and increases hepatic insulin responsiveness in diabetic rats. 2009 , 106, 11288-93	152
406	Long-term benefits of insulin therapy and glycemic control in overweight and obese adults with type 2 diabetes. 2009 , 23, 143-52	6
405	Anti-diabetic effect of American ginseng may not be linked to antioxidant activity: comparison between American ginseng and Scutellaria baicalensis using an ob/ob mice model. 2009 , 80, 306-11	17

404	Recent and emerging anti-diabetes targets. 2009 , 29, 125-95		70
403	The anti-diabetic effect of anthocyanins in streptozotocin-induced diabetic rats through glucose transporter 4 regulation and prevention of insulin resistance and pancreatic apoptosis. 2009 , 53, 1419-29		118
402	Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses. 2009 , 52, 1990-2000		86
401	Plasma proteome analysis for anti-obesity and anti-diabetic potentials of chitosan oligosaccharides in ob/ob mice. 2009 , 9, 2149-62		69
400	A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease. 2009 , 8, 38		36
399	Treating type 2 diabetes: how safe are current therapeutic agents?. 2009 , 63, 321-32		57
398	LCMSMS Development and Validation for Simultaneous Quantitation of Metformin, Glimepiride and Pioglitazone in Human Plasma and Its Application to a Bioequivalence Study. 2009 , 69, 1243-1250		46
397	Exenatide once weekly for the treatment of type 2 diabetes. 2009 , 18, 359-67		35
396	Oral hypoglycaemic drugs and newer agents use in Type 2 diabetes mellitus. 2009 , 51, 10-16		1
395	Antidiabetic effect of orally administered conophylline-containing plant extract on streptozotocin-treated and Goto-Kakizaki rats. <i>Biomedicine and Pharmacotherapy</i> , 2009 , 63, 710-6	7.5	35
394	Clustered metabolic abnormalities blunt regression of hypertensive left ventricular hypertrophy: the LIFE study. 2009 , 19, 634-40		26
393	Cinchonain Ib isolated from <i>Eriobotrya japonica</i> induces insulin secretion in vitro and in vivo. 2009 , 124, 224-7		47
392	Disruption of the allosteric phosphorylase a regulation of the hepatic glycogen-targeted protein phosphatase 1 improves glucose tolerance in vivo. 2009 , 21, 1123-34		31
391	Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies. 2009 , 3, 245-59		56
390	Diabetes Mellitus. 2009 , 9-16		
389	First-line drug management. 2009 , 20, 147-150		1
388	Diabetes Drugs: Present and Emerging. 2010 , 1-38		2
387	Living Well with Diabetes: a randomized controlled trial of a telephone-delivered intervention for maintenance of weight loss, physical activity and glycaemic control in adults with type 2 diabetes. 2010 , 10, 452		41

386	Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. 2010 , 116, 1938-46	233
385	Chemical composition and antidiabetic activity of Opuntia Milpa Alta extracts. 2010 , 7, 2869-79	23
384	Development of techniques for gastrojejunal bypass surgery in obese mice. 2010 , 30, 289-95	10
383	Glycemic and weight changes after persistent use of incident oral diabetes therapy: a Veterans Administration retrospective cohort study. 2010 , 19, 1108-12	13
382	Management of the diabetic patient with advanced chronic kidney disease. 2010 , 23, 140-7	14
381	Pioglitazone improvement of fasting and postprandial hyperglycaemia in Mexican-American patients with Type 2 diabetes: a double tracer OGTT study. 2010 , 73, 339-45	13
380	Drug utilization of oral hypoglycemic agents in a university teaching hospital in India. 2010 , 35, 267-77	26
379	Diabesity: therapeutic options. 2010 , 12, 463-73	81
378	Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. 2010 , 27, 309-17	158
377	Glipizide controlled-release tablets, with or without acarbose, improve glycaemic variability in newly diagnosed Type 2 diabetes. 2010 , 37, 564-8	19
376	The optimal extraction parameters and anti-diabetic activity of flavonoids from Ipomoea batatas leaf. 2009 , 6, 195-202	10
375	Effect of combined therapy of diabinese and nicotinic acid on liver enzymes in rabbits with dithizone-induced diabetes. 2010 , 2, 145-53	2
374	Complications and Management of Chronic Kidney Disease. 2010 , 145-163	1
373	Improving the reporting of adverse drug reactions in the hospital setting. 2010 , 122, 154-64	17
372	Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP-1 and IDPP-2). 2010 , 33, 2164-8	27
371	Strategies for the development of new PPAR agonists in diabetes. 2010 , 17 Suppl 1, S32-7	3
370	Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin. 2010 , 33, 951-7	90
369	Medications. 2010 , 26, 193-213	

368	Oral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of Action Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of Action. 2010 , 3, 3005-3020	67
367	Pharmacokinetics of metformin after enteral administration in insulin-resistant ponies. 2010 , 71, 1201-6	20
366	Metformin versus acarbose therapy in patients with polycystic ovary syndrome (PCOS): a prospective randomised double-blind study. 2010 , 26, 690-7	14
365	Novel therapeutics based on inhibiting the interaction of glycogen phosphorylase and GL-subunit of glycogen-associated protein phosphatase 1: WO2009127723. 2010 , 20, 969-73	6
364	New perspectives in type 2 diabetes, cardiovascular risk, and treatment goals. 2010 , 122, 52-60	16
363	Diabetic cardiomyopathy: signaling defects and therapeutic approaches. 2010 , 8, 373-91	45
362	Influence of glycemic control on the development of diabetic cardiovascular and kidney disease. 2010 , 28, 497-516	6
361	Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. 2010 , CD002967	162
360	Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. 2010 , CD002967	194
359	Diabetic macular edema: correlations with available diabetes therapies--evidence across a qualitative review of published literature from MEDLINE and EMBASE. 2010 , 33, 643-52	8
358	Optimizing insulin therapy in patients with type 1 and type 2 diabetes mellitus: optimal dosing and timing in the outpatient setting. 2010 , 56, 148-62	3
357	Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms. 2010 , 8, 359-72	81
356	Growth hormone can improve insulin resistance and differentiation in pancreas of senescence accelerated prone male mice (SAMP8). 2011 , 21, 63-8	10
355	Role of dipeptidyl peptidase IV (DPP4) in the development of dyslipidemia: DPP4 contributes to the steroid metabolism pathway. 2011 , 88, 43-9	19
354	Management of type 2 diabetes mellitus in the elderly. 2011 , 70, 151-9	30
353	Hypoglycemic activity of Thai medicinal plants selected from the Thai/Lanna Medicinal Recipe Database MANOSROI II. 2011 , 138, 92-8	19
352	Unit 5. Antidiabetic treatment options. 2011 , 22, 1-8	
351	Protective effect of salidroside from Rhodiolae Radix on diabetes-induced oxidative stress in mice. 2011 , 16, 9912-24	54

350	Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial(*). 2011 , 13, 81-8		79
349	Effects of chronic administration of alogliptin on the development of diabetes and β -cell function in high fat diet/streptozotocin diabetic mice. 2011 , 13, 337-47		45
348	Metformin should be considered in the treatment of gestational diabetes: a prospective randomised study. 2011 , 118, 880-5		123
347	Efficacy of chitooligosaccharides for the management of diabetes in alloxan induced mice: a correlative study with antihyperlipidemic and antioxidative activity. 2011 , 44, 534-43		36
346	Effect of a Pool of Peptides Isolated from <i>Crotalus durissus terrificus</i> (South American Rattlesnake) Venom on Glucose Levels of Mice Fed on a High-Fat Diet. 2011 , 17, 225-230		2
345	Enhanced glycemic control with combination therapy for type 2 diabetes in primary care. 2011 , 2, 162-77		10
344	Roux-en-Y gastric bypass-induced improvement of glucose tolerance and insulin resistance in type 2 diabetic rats are mediated by glucagon-like peptide-1. 2011 , 21, 1424-31		24
343	Guideline-conformity of initiation with oral hypoglycemic treatment for patients with newly therapy-dependent type 2 diabetes mellitus in Austria. 2011 , 20, 57-65		5
342	Direct activation of Epac by sulfonylurea is isoform selective. 2011 , 18, 243-51		41
341	Medication adherence in diabetes mellitus and self management practices among type-2 diabetics in Ethiopia. 2011 , 3, 418-23		81
340	Insulin resistance: pathophysiology and rationale for treatment. 2011 , 58, 25-36		23
339	Anti-diabetic effect of pyroglutamic acid in type 2 diabetic Goto-Kakizaki rats and KK-Ay mice. 2011 , 106, 995-1004		26
338	In silico identification of structure requirement for novel thiazole and oxazole derivatives as potent fructose 1,6-bisphosphatase inhibitors. <i>International Journal of Molecular Sciences</i> , 2011 , 12, 8161-80	6.3	6
337	Individualized treatment of type 2 diabetes mellitus using noninsulin agents: clinical considerations for the primary care physician. 2012 , 124, 95-108		6
336	Exenatide once weekly for the treatment of type 2 diabetes mellitus: clinical results in subgroups of patients using different concomitant medications. 2012 , 124, 33-40		9
335	Risico-allelen voor het ontstaan van Type 2 Diabetes Mellitus beïnvloeden de respons op sulfonylureumderivaten. 2012 , 10, 14-15		
334	Comparative effectiveness of incident oral antidiabetic drugs on kidney function. 2012 , 81, 698-706		61
333	Effects of pioglitazone add-on to gliclazide and metformin on glycemic control in patients with type 2 diabetes. 2012 , 37, 7-11		3

332	The management of type 2 diabetic patients with hypoglycaemic agents. 2012 , 2012, 478120	15
331	Metformin-Associated Lactic Acidosis following Intentional Overdose Successfully Treated with Tris-Hydroxymethyl Aminomethane and Renal Replacement Therapy. 2012 , 2012, 671595	6
330	Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients. 2012 , 22, 659-66	85
329	Antidiabetic Effect of Dieckol, a Marine Polyphenol, and Its Mechanisms of Blood Glucose Regulation. 2012 , 313-324	
328	Antidiabetic Compounds from Marine Organisms and Their Properties. 2012 , 7-20	
327	Prediabetes. 2012 , 57-75	1
326	Effects of bariatric surgery on glucose homeostasis and type 2 diabetes. 2012 , 143, 897-912	102
325	Disposition of metformin: variability due to polymorphisms of organic cation transporters. 2012 , 44, 119-29	59
324	Anti-diabetic effect of the soybean extract fermented by <i>Bacillus subtilis</i> MORI in db/db mice. 2012 , 21, 1669-1676	21
323	Atherogenesis and Diabetes: Focus on Insulin Resistance and Hyperinsulinemia. 2012 , 65, 309-313	2
322	The 2012 SEMDSA Guideline for the Management of Type 2 Diabetes (Revised). 2012 , 17, S1-S95	7
321	Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. 2012 , 35, 731-7	259
320	The 2012 SEMDSA Guideline for the Management of type 2 Diabetes. 2012 , 17, S1-S94	50
319	Atherogenesis and diabetes: focus on insulin resistance and hyperinsulinemia. 2012 , 65, 309-13	21
318	The effects of triple vs. dual and monotherapy with rosiglitazone, glimepiride, and atorvastatin on lipid profile and glycemic control in type 2 diabetes mellitus rats. 2012 , 26, 621-31	5
317	Nuciferine stimulates insulin secretion from beta cells-an in vitro comparison with glibenclamide. 2012 , 142, 488-95	60
316	Effects of brown alga, <i>Ecklonia cava</i> on glucose and lipid metabolism in C57BL/KsJ-db/db mice, a model of type 2 diabetes mellitus. 2012 , 50, 575-82	75
315	Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years. 2012 , 34, 2082-90	15

314	Traditional medicinal herbs and food plants have the potential to inhibit key carbohydrate hydrolyzing enzymes in vitro and reduce postprandial blood glucose peaks in vivo. 2012 , 2012, 285284	29
313	Efeito do treinamento combinado e aer�bio no controle glic�mico no diabetes tipo 2. 2012 , 25, 399-409	0
312	Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of twice-daily exenatide. 2012 , 18, 227-37	11
311	Dapagliflozin: an evidence-based review of its potential in the treatment of type-2 diabetes. 2012 , 7, 21-8	8
310	Association of acanthosis nigricans and skin tags with insulin resistance. 2012 , 87, 97-104	38
309	Mechanistic studies on the antidiabetic activity of a polysaccharide-rich extract of Radix Ophiopogonis. 2012 , 26, 101-5	14
308	Functional Food Components for Preventing and Combating Type 2 Diabetes. 2012 , 345-374	3
307	Discrete effects of glimepiride and metformin on preprandial and postprandial glucose and contributions to the amelioration of chronic hyperglycemia. 2012 , 3, 21-28	
306	Inhibitory potential of trilobatin from Lithocarpus polystachyus Rehd against �glucosidase and �mylase linked to type 2 diabetes. 2012 , 130, 261-266	155
305	Constitutive androstane receptor activation by 2,4,6-triphenyldioxane-1,3 suppresses the expression of the gluconeogenic genes. 2012 , 679, 139-43	20
304	Oral Hypoglycemic Agents in pregnancy: An Update. 2013 , 63, 82-7	17
303	Treatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in Argentina. 2013 , 3, 11	17
302	Suicide commitment with metformin: our experience with five cases. 2013 , 35, 863-5	9
301	Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. 2013 , 36, 1304-11	239
300	Evaluation of the inhibition of carbohydrate hydrolysing enzymes, antioxidant activity and polyphenolic content of extracts of ten African Ficus species (Moraceae) used traditionally to treat diabetes. 2013 , 13, 94	52
299	Six-month outcomes from living well with diabetes: A randomized trial of a telephone-delivered weight loss and physical activity intervention to improve glycemic control. 2013 , 46, 193-203	27
298	A comparison between metformin and garlic on alloxan-induced diabetic dogs. 2013 , 22, 169-174	1
297	Insulin use early in the course of type 2 diabetes mellitus: the ORIGIN trial. 2013 , 13, 342-9	17

296	Kiwifruit (<i>Actinidia chinensis</i>) extract annuls chronic insulin-induced insulin resistance in l6 skeletal muscle cells. 2013 , 22, 1091-1096	4
295	Constituents from <i>Terminalia</i> species increase PPAR α and PPAR γ levels and stimulate glucose uptake without enhancing adipocyte differentiation. 2013 , 149, 490-8	44
294	The role of pharmacogenetics in drug disposition and response of oral glucose-lowering drugs. 2013 , 52, 833-54	22
293	Effect of low molecular weight galactomannans from fenugreek seeds on animal models of diabetes mellitus. 2013 , 3, 145-151	52
292	α -Amylase inhibitory activity from nut seed skin polyphenols. 1. Purification and characterization of almond seed skin polyphenols. 2013 , 61, 4570-6	40
291	Isolation and quantification of flavonoids from ethanol extract of <i>Costus igneus</i> rhizome (CiREE) and impact of CiREE on hypoglycaemic, electron microscopic studies of pancreas in streptozotocin (STZ)-induced diabetic rats. 2013 , 3, 285-297	4
290	Structural characteristics and hypoglycemic activity of polysaccharides from <i>Coprinus comatus</i> . 2013 , 2, 164-169	23
289	Noninsulin glucose-lowering agents for the treatment of patients on dialysis. 2013 , 9, 147-53	23
288	Protective effect of vanadyl sulfate on skin injury in streptozotocin-induced diabetic rats. 2013 , 32, 1206-12	11
287	Anti-diabetic effects of brown algae derived phlorotannins, marine polyphenols through diverse mechanisms. 2013 , 86, 129-36	148
286	Metformin in dermatology: an overview. 2013 , 27, 1329-35	29
285	The Role of Pharmacogenomics in Diabetes, HIV Infection, and Pain Management. 2013 , 247-271	
284	Efficacy and safety of glimepiride/metformin sustained release once daily vs. glimepiride/metformin twice daily in patients with type 2 diabetes. 2013 , 67, 236-43	8
283	Mechanisms for food polyphenols to ameliorate insulin resistance and endothelial dysfunction: therapeutic implications for diabetes and its cardiovascular complications. 2013 , 305, E679-86	67
282	The TRPA1 channel and oral hypoglycemic agents: is there complicity in β cell exhaustion?. 2013 , 7, 420-2	9
281	<i>Loranthus micranthus</i> Linn.: Biological Activities and Phytochemistry. 2013 , 2013, 273712	15
280	Evaluation of efficacy and tolerability of glimepiride and metformin combination: a multicentric study in patients with type-2 diabetes mellitus, uncontrolled on monotherapy with sulfonylurea or metformin. 2013 , 20, 41-7	6
279	Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. 2013 , 36 Suppl 2, S127-38	179

278	Safety and efficacy of sitagliptin-metformin in fixed combination for the treatment of type 2 diabetes mellitus. 2013 , 6, 25-37	6
277	Nutrigenomic effects of germinated brown rice and its bioactives on hepatic gluconeogenic genes in type 2 diabetic rats and HEPG2 cells. 2013 , 57, 401-11	23
276	Fatigue and related factors in people with type 2 diabetes. 2013 , 39, 320-6	26
275	Antihyperglycemic, antihyperlipidemic, anti-inflammatory and adenosine deaminase- lowering effects of garlic in patients with type 2 diabetes mellitus with obesity. 2013 , 6, 49-56	70
274	Phytol/Phytanic acid and insulin resistance: potential role of phytanic acid proven by docking simulation and modulation of biochemical alterations. 2013 , 8, e45638	65
273	Severe lactic acidosis and acute pancreatitis associated with cimetidine in a patient with type 2 diabetes mellitus taking metformin. 2013 , 52, 2245-8	12
272	Evaluation of the inhibition of carbohydrate hydrolyzing enzymes, the antioxidant activity, and the polyphenolic content of Citrus limetta peel extract. 2014 , 2014, 121760	25
271	Leucaena leucocephala fruit aqueous extract stimulates adipogenesis, lipolysis, and glucose uptake in primary rat adipocytes. 2014 , 2014, 737263	4
270	Fermentation with Aquilariae Lignum enhances the anti-diabetic activity of green tea in type II diabetic db/db mouse. 2014 , 6, 3536-71	48
269	Optimal management of type 2 diabetes in patients with increased risk of hypoglycemia. 2014 , 7, 85-94	7
268	Prescribing pattern and efficacy of anti-diabetic drugs in maintaining optimal glycemc levels in diabetic patients. 2014 , 5, 79-83	36
267	Glycaemic control in diabetic patients in Zambia. 2014 , 19, 354	11
266	Antidiabetic potentials of essential oil extracted from the leaves of Hoslundia opposita Vahl. 2014 , 17, 1122-8	11
265	Diabetes and related remedies in medieval Persian medicine. 2014 , 18, 142-9	24
264	Diabetes as a Disease of Aging, and the Role of Oxidative Stress. 2014 , 61-69	0
263	Virtual Systems Pharmacology (ViSP) software for simulation from mechanistic systems-level models. 2014 , 5, 232	11
262	Comparison of three α -glucosidase inhibitors for glycemc control and bodyweight reduction in Japanese patients with obese type 2 diabetes. 2014 , 5, 206-12	30
261	Factors associated with good glycemc control among patients with type 2 diabetes mellitus. 2014 , 5, 563-9	51

260	Pharmacist review prevents evolving metformin-associated lactic acidosis. 2014 , 39, 567-70	4
259	Prandial insulin versus glucagon-like peptide-1 added to basal insulin: comparative effectiveness in the community practice setting. 2014 , 126, 49-59	1
258	Targets and candidate agents for type 2 diabetes treatment with computational bioinformatics approach. 2014 , 2014, 763936	11
257	Evaluation of hypoglycemic activity of total lignans from Fructus Arctii in the spontaneously diabetic Goto-Kakizaki rats. 2014 , 151, 548-55	31
256	Inhibitory effect of eleven herbal extracts on advanced glycation end-products formation and aldose reductase activity. 2014 , 25, 1039-1043	10
255	Olive leaf extract suppresses messenger RNA expression of proinflammatory cytokines and enhances insulin receptor substrate 1 expression in the rats with streptozotocin and high-fat diet-induced diabetes. 2014 , 34, 450-7	32
254	Anti-diabetic potential of Panax notoginseng saponins (PNS): a review. 2014 , 28, 510-6	80
253	Pyridazine and its related compounds. Part 34. Hypoglycemic and hypolipidemic activity of some novel condensed pyridazine sulfonamides. 2014 , 23, 34-41	5
252	Duodenal-jejunal bypass liner to treat type 2 diabetes mellitus in morbidly obese patients. 2014 , 16, 454	8
251	Glycemic Control. 2014 , 205-214	
250	Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials. 2014 , 30, 241-56	55
249	Preventive effect of Monascus-fermented products enriched with ubiquinones on type 2 diabetic rats induced by a high-fructose plus high-fat diet. 2014 , 17, 826-9	6
248	The effects of chitosan oligosaccharide (GO2KA1) supplementation on glucose control in subjects with prediabetes. 2014 , 5, 2662-9	36
247	Phenolic-Linked Antioxidant, anti-Diabetic, and anti-Hypertensive Potential of Wild and Cultivated Swertia chirayita (Roxb. ex Flem.) Karst. Using in vitro Assays. 2014 , 20, 55-69	5
246	Glucose control: Non-insulin therapies. 2014 , 56, 21-30	
245	Antidiabetogenic and antioxidative effects of octaphlorethol a isolated from the brown algae Ishige foliacea in streptozotocin-induced diabetic mice. 2014 , 23, 1261-1266	8
244	Lipid profiling reveals different therapeutic effects of metformin and glipizide in patients with type 2 diabetes and coronary artery disease. 2014 , 37, 2804-12	18
243	Evaluation of pharmacokinetic drug interactions between gemigliptin (dipeptidylpeptidase-4 inhibitor) and glimepiride (sulfonylurea) in healthy volunteers. 2014 , 14, 165-76	5

242	L-carnitine and PPAR α agonist fenofibrate are involved in the regulation of Carnitine Acetyltransferase (CrAT) mRNA levels in murine liver cells. 2014 , 15, 514	5
241	Antidiabetic effects of <i>Mukia maderaspatana</i> and its phenolics: an in vitro study on gluconeogenesis and glucose uptake in rat tissues. 2014 , 52, 597-602	10
240	Use of metformin in diseases of aging. 2014 , 14, 490	23
239	Incidence of lactic acidosis in patients with type 2 diabetes with and without renal impairment treated with metformin: a retrospective cohort study. 2014 , 37, 2291-5	67
238	Therapeutic adherence: A prospective drug utilization study of oral hypoglycemic in patients with type 2 diabetes mellitus. 2014 , 4, S347-S352	3
237	Disease burden of urinary tract infections among type 2 diabetes mellitus patients in the U.S. 2014 , 28, 621-6	32
236	Design, synthesis and glucose uptake activity of some novel glitazones. 2014 , 56, 27-33	22
235	Efficacy of natural diosgenin on cardiovascular risk, insulin secretion, and beta cells in streptozotocin (STZ)-induced diabetic rats. 2014 , 21, 1154-61	63
234	Oral administration of soybean peptide Vglycin normalizes fasting glucose and restores impaired pancreatic function in Type 2 diabetic Wistar rats. 2014 , 25, 954-63	23
233	Antioxidant, Antidiabetic and Chemical Composition of <i>Syzygium Aqueum</i> Leaf Extracts. 2014 , 187-228	
232	Clinical management of hyperglycaemia in type 2 diabetes. 2015 , 103-111	
231	WITHDRAWN: Metformin monotherapy for type 2 diabetes mellitus. 2015 , CD002966	1
230	An in silico insight into novel therapeutic interaction of LTNF peptide-LT10 and design of structure based peptidomimetics for putative anti-diabetic activity. 2015 , 10, e0121860	7
229	Synthesis and Evaluation of Novel Triterpene Analogues of Ursolic Acid as Potential Antidiabetic Agent. 2015 , 10, e0138767	13
228	Antidiabetic Activity of <i>Ruellia tuberosa</i> L., Role of α -Amylase Inhibitor: In Silico, In Vitro, and In Vivo Approaches. 2015 , 2015, 349261	15
227	Evidence for organic cation transporter-mediated metformin transport and 5 α -adenosine monophosphate-activated protein kinase activation in rat skeletal muscles. 2015 , 64, 296-304	10
226	Anti-hyperglycemic and hypolipidemic effects of baechukimchi with <i>Ecklonia cava</i> in type 2 diabetic db/db mice. 2015 , 24, 307-314	2
225	Efficacy and safety of a dieckol-rich extract (AG-dieckol) of brown algae, <i>Ecklonia cava</i> , in pre-diabetic individuals: a double-blind, randomized, placebo-controlled clinical trial. 2015 , 6, 853-8	43

224	Synthesis and evaluation of multi-functional NO-donor/insulin-secretagogue derivatives for the treatment of type II diabetes and its cardiovascular complications. 2015 , 23, 422-8	4
223	Prescribing patterns and changes in initial oral antidiabetic agents for Korean type 2 diabetic patients. 2015 , 35, 304-309	
222	Benzothiazole derivatives upregulate SIRT1 and relevant genes in high-fat fed C57BL/6J mice. 2015 , 24, 2454-2460	1
221	Efficacy and safety of sitagliptin compared with sulfonylurea therapy in patients with type 2 diabetes showing inadequately controlled glycosylated hemoglobin with metformin monotherapy: A meta-analysis. 2015 , 9, 1528-1536	9
220	The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats. 2015 , 127, 456-61	21
219	The relationship between type 2 diabetic patients' early medical care-seeking consistency to the same clinician and health care system and their clinical outcomes. 2015 , 94, e554	13
218	Padina arborescens Ameliorates Hyperglycemia and Dyslipidemia in C57BL/KsJ-db/db Mice, a Model of Type 2 Diabetes Mellitus. 2015 , 18, 1088-94	7
217	Selenite exacerbates hepatic insulin resistance in mouse model of type 2 diabetes through oxidative stress-mediated JNK pathway. 2015 , 289, 409-18	29
216	Synthetic (+)-antroquinonol exhibits dual actions against insulin resistance by triggering AMP kinase and inhibiting dipeptidyl peptidase IV activities. 2015 , 172, 38-49	16
215	Patterns of glucose lowering drugs utilization in Portugal and in the Netherlands. Trends over time. 2015 , 9, 482-9	17
214	Therapeutic potential of α -glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review. 2015 , 16, 1959-81	142
213	The treatment of type 1 diabetes mellitus with agents approved for type 2 diabetes mellitus. 2015 , 16, 2331-41	13
212	Matrix tablets for sustained release of repaglinide: Preparation, pharmacokinetics and hypoglycemic activity in beagle dogs. 2015 , 478, 297-307	18
211	Metformin for primary colorectal cancer prevention in patients with diabetes: a case-control study in a US population. 2015 , 121, 1071-8	64
210	Effects of Cyclo-His-Pro-enriched yeast hydrolysate on blood glucose levels and lipid metabolism in obese diabetic ob/ob mice. 2016 , 10, 154-60	5
209	Patient considerations in type 2 diabetes - role of combination dapagliflozin-metformin XR. 2016 , 9, 25-35	6
208	Fenofibrate plus Metformin Produces Cardioprotection in a Type 2 Diabetes and Acute Myocardial Infarction Model. 2016 , 2016, 8237264	26
207	Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agents. 2016 , 9, 17-29	11

206	Alterations of voltage-dependent K(+) channels in the mesenteric artery during the early and chronic phases of diabetes. 2016 , 43, 808-17	7
205	Diabetes and oral therapies: A review of oral therapies for diabetes mellitus. 2016 , 11, 317-329	20
204	Beneficial effects of combined resveratrol and metformin therapy in treating diet-induced insulin resistance. 2016 , 4, e12877	26
203	Effect of Serotonin Transporter 5-HTTLPR Polymorphism on Gastrointestinal Intolerance to Metformin: A GoDARTS Study. 2016 , 39, 1896-1901	31
202	Persimmon-Tannin, an α -Amylase Inhibitor, Retards Carbohydrate Absorption in Rats. 2016 , 62, 192-7	4
201	Mulberry (<i>Morus alba</i> L.) Fruit Extract Containing Anthocyanins Improves Glycemic Control and Insulin Sensitivity via Activation of AMP-Activated Protein Kinase in Diabetic C57BL/Ksj-db/db Mice. 2016 , 19, 737-45	49
200	Metformin and sulphonylurea (second- or third-generation) combination therapy for adults with type 2 diabetes mellitus. 2016 ,	1
199	Early insulin therapy in patients with type 2 diabetes mellitus. 2016 , 21, 13-15	4
198	Inhibition of Porcine Pancreatic Amylase Activity by Sulfamethoxazole: Structural and Functional Aspect. 2016 , 35, 237-46	8
197	Genetic markers predicting sulphonylurea treatment outcomes in type 2 diabetes patients: current evidence and challenges for clinical implementation. 2016 , 16, 209-19	21
196	Metabolomic biomarkers for personalised glucose lowering drugs treatment in type 2 diabetes. 2016 , 12, 27	23
195	Progression to treatment failure among Chinese patients with type 2 diabetes initiated on metformin versus sulphonylurea monotherapy--The Hong Kong Diabetes Registry. 2016 , 112, 57-64	4
194	Therapeutic potential of the dual peroxisome proliferator activated receptor (PPAR) α agonist aleglitazar in attenuating TNF α -mediated inflammation and insulin resistance in human adipocytes. 2016 , 107, 125-136	35
193	Type 2 Diabetes Medication Review. 2016 , 351, 342-55	18
192	Anti-oxidant and antidiabetic effect of some medicinal plants belong to Terminalia species collected in Dak Lak Province, Vietnam. 2016 , 42, 5859-5871	19
191	Neuroprotective effects of metformin against A β -mediated inhibition of long-term potentiation in rats fed a high-fat diet. 2016 , 121, 178-85	58
190	Octaphlorethol A, a marine algae product, exhibits antidiabetic effects in type 2 diabetic mice by activating AMP-activated protein kinase and upregulating the expression of glucose transporter 4. 2016 , 91, 58-64	37
189	Estimaci3n de los costes directos institucionales para la atenci3n de salud de la diabetes en Cuba, 2008-2011. 2016 , 13, 37-47	

188	In vitro effects of bis(1,2-dimethyl-3-hydroxy-4-pyridinonato)oxidovanadium(IV), or VO(dmpp) ₂ , on insulin secretion in pancreatic islets of type 2 diabetic Goto-Kakizaki rats. 2016 , 154, 29-34	10
187	Conditioned Media From Adipose Tissue Derived Mesenchymal Stem Cells Reverse Insulin Resistance in Cellular Models. 2017 , 118, 2037-2043	20
186	Factors of primary and secondary sulfonylurea failure in type 2 diabetic subjects. 2017 , 9, 1091-1099	2
185	Free radical scavenging and antidiabetic activities of <i>Euonymus laxiflorus</i> Champ. extract. 2017 , 43, 5615-5624	13
184	Advantages of the polysaccharides from <i>Gracilaria lemaneiformis</i> over metformin in antidiabetic effects on streptozotocin-induced diabetic mice. 2017 , 7, 9141-9151	29
183	Metformin combined with acarbose vs. single medicine in the treatment of type 2 diabetes: A meta-analysis. 2017 , 13, 3137-3145	6
182	Xanthones from the twigs of <i>Garcinia oblongifolia</i> and their antidiabetic activity. 2017 , 118, 126-131	13
181	Phospholipid complex enriched micelles: A novel drug delivery approach for promoting the antidiabetic effect of repaglinide. 2017 , 99, 75-84	32
180	Iminosugars Spiro-Linked with Morpholine-Fused 1,2,3-Triazole: Synthesis, Conformational Analysis, Glycosidase Inhibitory Activity, Antifungal Assay, and Docking Studies. 2017 , 2, 7203-7218	20
179	Effect of Aloe vera on glycemic outcomes in patients with diabetes mellitus: a systematic review protocol. 2017 , 15, 2300-2306	3
178	Abnormalities in alternative splicing in diabetes: therapeutic targets. 2017 , 59, R93-R107	24
177	Long-term management of type 2 diabetes mellitus in callitrichids with oral anti-hyperglycaemic medication. 2017 , 51, 258-268	3
176	Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study. 2017 , 60, 1601-1611	86
175	Using Personalized Medicine in the Management of Diabetes Mellitus. 2017 , 37, 1131-1149	5
174	Release of dipeptidyl peptidase IV, α -amylase and α -glucosidase inhibitory peptides from quinoa (<i>Chenopodium quinoa</i> Willd.) during in vitro simulated gastrointestinal digestion. 2017 , 35, 531-539	116
173	KCNJ11, ABCC8 and TCF7L2 polymorphisms and the response to sulfonylurea treatment in patients with type 2 diabetes: a bioinformatics assessment. 2017 , 18, 64	16
172	Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective. 2017 , 39, 1012-1025	12
171	Incidence and predictors of type 2 diabetes among Koreans: A 12-year follow up of the Korean Genome and Epidemiology Study. 2017 , 123, 173-180	34

170	Dammarane-type triterpene extracts of Panax notoginseng root ameliorates hyperglycemia and insulin sensitivity by enhancing glucose uptake in skeletal muscle. 2017 , 81, 335-342	15
169	Inhibitory activities of Cystoseira crinita sulfated polysaccharide on key enzymes related to diabetes and hypertension: in vitro and animal study. 2017 , 123, 31-42	13
168	Chinese Olive (Canarium album L.) Fruit Extract Attenuates Metabolic Dysfunction in Diabetic Rats. 2017 , 9,	14
167	Diabetes Mellitus and Risk of Hepatocellular Carcinoma. <i>BioMed Research International</i> , 2017 , 2017, 5203684	29
166	Bioactivity-Guided Isolation of Potential Antidiabetic and Antihyperlipidemic Compounds from Trigonella stellata. 2018 , 81, 1154-1161	8
165	A small dose of whey protein co-ingested with mixed-macronutrient breakfast and lunch meals improves postprandial glycemia and suppresses appetite in men with type 2 diabetes: a randomized controlled trial. 2018 , 107, 550-557	31
164	Investigation of the therapy targets of Yi-Qi-Yang-Yin-Hua-Tan-Qu-Yu recipe on type 2 diabetes by serum proteome labeled with iTRAQ. 2018 , 224, 1-14	4
163	Metformin monotherapy for adults with type 2 diabetes mellitus. 2018 ,	3
162	Anti-diabetic activity of quercetin extracted from L. fruit: and approaches. 2018 , 8, 109-118	61
161	Comparative effectiveness of metformin monotherapy in extended release and immediate release formulations for the treatment of type 2 diabetes in treatment-naïve Chinese patients: Analysis of results from the CONSENT trial. 2018 , 20, 1006-1013	11
160	Nigella sativa Oil and Chromium Picolinate Ameliorate Fructose-Induced Hyperinsulinemia by Enhancing Insulin Signaling and Suppressing Insulin-Degrading Enzyme in Male Rats. 2018 , 184, 119-126	8
159	Obesity alters the uterine environment before pregnancy. 2018 , 62, 181-191	0
158	The Effect of L. Fruit Juice on the Blood Sugar Level and Other Serum Parameters in Patients with Diabetes Type 2. 2018 , 2018, 3565427	10
157	Prediabetes: Prevalence, Pathogenesis, and Recognition of Enhanced Risk. 2018 , 15-32	1
156	Reactive Oxygen Species-mediated Degradation of Antidiabetic Compounds: Cytotoxic Implications of Their Photodegradation Products. 2018 , 94, 1151-1158	0
155	Development and validation of a new analytical HPLC method for simultaneous determination of the antidiabetic drugs, metformin and gliclazide. 2019 , 27, 315-322	22
154	Factors associated with physicians' decision to discontinue or down-titrate sulfonylureas for type 2 diabetes patients. 2019 , 19, 71-79	7
153	Diabetes: Its Implications, Diagnosis, Treatment, and Management. 2019 , 1-12	

152	Development of a Novel Series of Anticancer and Antidiabetic: Spirothiazolidines Analogs. 2019 , 24,	12
151	Assessment of clinical and biochemical profile of prediabetic subject in Bangladesh, attending in BIRDEM and results of intervention by lifestyle modification, metformin, and DPP4 inhibitor. 2019 , 13, 1603-1608	4
150	Chitosan oligosaccharide (GO2KA1) improves postprandial glycemic response in subjects with impaired glucose tolerance and impaired fasting glucose and in healthy subjects: a crossover, randomized controlled trial. 2019 , 9, 31	14
149	Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus. 2019 , 4, CD012368	13
148	Upregulation of GABA receptor promotes long-term potentiation and depotentiation in the hippocampal CA1 region of mice with type 2 diabetes mellitus. 2019 , 18, 2429-2436	4
147	Antidiabetic Potential of Medicinal Plants and Their Active Components. 2019 , 9,	155
146	The Role of Pharmacogenomics in Diabetes. 2019 , 247-269	
145	Structural elucidation and bioactivities of a novel arabinogalactan from <i>Coreopsis tinctoria</i> . 2019 , 219, 219-228	19
144	A novel strategy of nanotized herbal drugs and their delivery in the treatment of diabetes: Present status and future prospects. 2019 , 17-18, 100279	5
143	Ginsenoside Rb1 as an Anti-Diabetic Agent and Its Underlying Mechanism Analysis. 2019 , 8,	93
142	Spatial and temporal studies of metabolic activity: contrasting biochemical kinetics in tissues and pathways during fasted and fed states. 2019 , 316, E1105-E1117	6
141	Adverse Effects of Glycemia-Lowering Medications in Type 2 Diabetes. 2019 , 19, 132	3
140	Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. 2019 , 12, CD008558	12
139	SGLT2 inhibitors and metformin: Dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes. 2019 , 846, 23-29	20
138	Ameliorative potential of acupuncture on gestational diabetes mellitus: A randomized controlled trial. 2018 , 16,	1
137	Using a semi-mechanistic model to identify the main sources of variability of metformin pharmacokinetics. 2019 , 124, 105-114	3
136	Determinants of glycemic control: Phase 2 analysis from nationwide diabetes report of National Program for Prevention and Control of Diabetes (NPPCD-2018). 2020 , 14, 222-231	6
135	Metformin in the prevention of hepatocellular carcinoma in diabetic patients: A systematic review. 2020 , 19, 232-237	33

134	Educational weight loss interventions in obese and overweight adults with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. 2020 , 37, 623-635	9
133	Coumarins and acridone alkaloids with α -glucosidase inhibitory and antioxidant activity from the roots of <i>Paramignya trimera</i> . 2020 , 35, 94-98	6
132	Hypoglycaemic effect of all-trans astaxanthin through inhibiting α -glucosidase. 2020 , 74, 104168	9
131	Phlorotannins: From isolation and structural characterization, to the evaluation of their antidiabetic and anticancer potential. 2020 , 137, 109589	24
130	Essential oil composition and biological activities of Poir (Fabaceae). 2020 , 1-6	2
129	Bioactive Compounds in Anti-Diabetic Plants: From Herbal Medicine to Modern Drug Discovery. 2020 , 9,	35
128	Pharmacogenetics of Type 2 Diabetes-Progress and Prospects. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3 13
127	Time-Restricted Feeding and Potential for Type 2 Diabetes Mellitus: A Narrative Review. 2020 ,	1
126	Effects of Pregnancy on the Pharmacokinetics of Metformin. 2020 , 48, 264-271	15
125	Metformin monotherapy for adults with type 2 diabetes mellitus. 2020 , 6, CD012906	9
124	A novel non-PPAR γ insulin sensitizer: MLR-1023 clinical proof-of-concept in type 2 diabetes mellitus. 2020 , 34, 107555	8
123	Changing Fields-Diabetes Medications Invading the Cardiovascular Space. 2021 , 46, 100736	1
122	Antidiabetic Property of Aloe vera (<i>Aloe barbadensis</i>) and Bitter Melon (<i>Momordica charantia</i>). 2021 , 257-269	1
121	Influence of Administering Watermelon Rind Water Extract (<i>Citrullus vulgaris</i> Schard) on Glucose Level of Male White Rats (<i>Rattus norvegicus</i>) Induced with Streptozotocin. 2021 , 56, 174	
120	An Overview of Hypoglycemic Modern Drugs. 2021 , 17-32	1
119	Severe hypoglycaemia under abemaciclib administration in a patient with breast cancer: A case report. 2021 , 14, 61	1
118	Mechanistic Insights into Side Effects of Troglitazone and Rosiglitazone Using a Novel Inverse Molecular Docking Protocol. 2021 , 13,	8
117	HM-chromanone, a component of <i>Portulaca oleracea</i> L., stimulates glucose uptake and glycogen synthesis in skeletal muscle cell. 2021 , 83, 153473	2

116	Sleeping Duration, Napping and Snoring in Association with Diabetes Control among Patients with Diabetes in Qatar. 2021 , 18,	1
115	Focused Ultrasound Modulation of Hepatic Neural Plexus Restores Glucose Homeostasis in Diabetes.	
114	Clinical potentials of ginseng polysaccharide for treating gestational diabetes mellitus. 2021 , 9, 4959-4979	1
113	Meta-Assessment of Metformin Absorption and Disposition Pharmacokinetics in Nine Species. 2021 , 14,	2
112	Metformin restores hippocampal neurogenesis and learning and memory via regulating gut microbiota in the obese mouse model. 2021 , 95, 68-83	12
111	Study of the antioxidant and antidiabetic activity in vitro of free and encapsulated phenolic compounds of olive pomace. 2021 , 36, 102126	2
110	Hypoglycemic effect of astragaloside IV via modulating gut microbiota and regulating AMPK/SIRT1 and PI3K/AKT pathway. 2021 , 281, 114558	5
109	Highly enantioselective access to chiral chromanes and thiochromanes via Cu-catalyzed hydroamination with anthranils. 2021 , 8, 1563-1568	3
108	Combination Therapy in Type 2 Diabetes.	2
107	New Drugs for the Treatment of Diabetes Mellitus.	1
106	Postharvest Strategies to Enhance Bioactive Ingredients for Type 2 Diabetes Management and Heart Health. 357-379	1
105	Hypoglycaemia in Type 2 Diabetes and in Elderly People. 230-262	2
104	Therapeutic Strategies Exploiting DP IV Inhibition. 2002 , 259-278	4
103	Oral Agents for Type-2 Diabetes. 2011 , 93-122	1
102	Targeting type 2 diabetes. 2011 , 1-33	6
101	NHG-Standaard Diabetes mellitus type 2. 2009 , 160-191	4
100	NHG-Standaard Diabetes mellitus type 2. 2011 , 1305-1336	0
99	Exercise improves metformin 72-h glucose control by reducing the frequency of hyperglycemic peaks. 2020 , 57, 715-723	8

98	DIABETES MELLITUS. 2009 , 557-570		1
97	Perioperative care of diabetic patients. 2001 , 18, 277-294		9
96	Strategies for insulin therapy in type 2 diabetes. 2005 , 98, 363-71		15
95	Treating the whole patient for optimal management of type 2 diabetes: considerations for insulin therapy. 2007 , 100, 804-11		5
94	Addressing cultural barriers to the successful use of insulin in Hispanics with type 2 diabetes. 2007 , 100, 812-20		37
93	The glitazones: proceed with caution. 2000 , 173, 54-7		29
92	The target for good glycemic control should be an Hb A(1C) concentration of less than 0.07. 2000 , 173, 179-80		5
91	Adding pioglitazone to insulin containing regimens in type 2 diabetes: systematic review and meta-analysis. 2009 , 4, e6112		25
90	Transcriptomic analysis of insulin-sensitive tissues from anti-diabetic drug treated ZDF rats, a T2DM animal model. 2013 , 8, e69624		2
89	Sulfonylureas may be useful for glycemic management in patients with diabetes and liver cirrhosis. 2020 , 15, e0243783		2
88	α-Glucosidase Inhibition Kinetics and Molecular Docking Studies with the Bioactive Constituents from Canna indica L. Rhizome Extract. 2020 , 32, 1986-1990		2
87	Prevention and treatment of type 2 diabetes mellitus in children, with special emphasis on American Indian and Alaska Native children. American Academy of Pediatrics Committee on Native American Child Health. 2003 , 112, e328		80
86	What's next after metformin? focus on sulphonylurea: add-on or combination therapy. <i>Pharmacy Practice</i> , 2015 , 13, 606	1.8	8
85	Chapter 10 Diabetes. 2010 ,		1
84	Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes. 2006 , 2, 69-77		23
83	Effect of Sitagliptin and Metformin on Prediabetes Progression to Type 2 Diabetes - A Randomized, Double-Blind, Double-Arm, Multicenter Clinical Trial: Protocol for the Sitagliptin and Metformin in PreDiabetes (SiMePreD) Study. 2016 , 5, e145		7
82	Effects of the Combined Extracts of Grape Pomace and Omija Fruit on Hyperglycemia and Adiposity in Type 2 Diabetic Mice. 2015 , 20, 94-101		6
81	Antihyperglycemic, Antihyperlipidemic and Antioxidant Effects of Zizyphus spina christi and Zizyphus jujuba in Alloxan Diabetic Rats. 2006 , 2, 563-570		15

80	Purified Methanolic Extract of <i>Salacia reticulata</i> Wight. Ameliorates Insulin Resistance and Metabolic Alterations in Rats Fed High Fructose Diet. 2010 , 6, 386-392		3
79	Antioxidant, Antidiabetic and Antihyperlipidemic Effects of <i>Trigonella foenum-graecum</i> Seeds. 2016 , 12, 394-400		7
78	Comparative Evaluation of the Protective Effect of the Ethanolic and Methanolic Leaf Extracts of <i>Sida acuta</i> Against Hyperglycaemia and Alterations of Biochemical and Haematological Indices in Alloxan Diabetic Rats. 2009 , 5, 1-12		7
77	Preparation and crystallographic analysis of gliclazide polymorphs. 2015 , 77, 34-40		5
76	Comparative molecular field analysis of benzothiazepine derivatives: mitochondrial sodium calcium exchange inhibitors as antidiabetic agents. 2008 , 70, 186-92		2
75	Herbal therapy: A review of emerging pharmacological tools in the management of diabetes mellitus in Africa. 2015 , 11, S258-74		16
74	An unusual case of glipizide-induced proximal myopathy. 2016 , 7, 99-101		1
73	Potential medicinal benefits of <i>Cosmos caudatus</i> (Ulam Raja): A scoping review. 2015 , 20, 1000-6		9
72	In vitro studies on the inhibition of α -amylase and α -glucosidase by hydro-ethanolic extract of <i>Pluchea lanceolata</i> , <i>Alhagi pseudalhagi</i> , <i>Caesalpinia bonduc</i> . <i>Pharmacognosy Research (discontinued)</i> , 2019 , 11, 310	0.7	11
71	Glycemic relapse in type 2 diabetes. 2006 , 12, 145-51		5
70	Discontinuation of metformin in the setting of coronary angiography: clinical uncertainty amongst physicians reflecting a poor evidence base. 2012 , 7, 1103-10		10
69	Antihyperlipidemic Effect of Ginsenoside Rg1 in Type 2 Diabetic Mice. 2011 , 21, 932-938		3
68	EXTRACTION OPTIMIZATION OF <i>Senecio vernalis</i> Waldst. & Kit AND DETERMINATION OF ANTI- α -AMYLASE/ α -GLUCOSIDASE, ANTI-LIPASE AND ANTIOXIDANT ACTIVITIES.		
67	Postoperative Management of Diabetes. 2001 , 533-546		
66	Pathophysiologie des Diabetes mellitus Typ2. 2001 , 31-48		
65	Risikofaktoren der KHK und Möglichkeiten ihrer Reduzierung. 2002 , 67-92		
64	Are Thiazolidinediones Superior to Standard Therapy in the Treatment of Type 2 Diabetes?. 2002 , 149-155		
63	Causal Connections. 2002 , 1-8		

62 Islet Amyloid Polypeptide/GLP-1/Exendin.

61 Pathogenesis and Management of Non-alcoholic Steatohepatitis. **2005**, 48, 169

60 Carbohydrate Mimetics in Drug Discovery. **2005**,

59 Nutritional Strategies for Patients with Obesity and the Metabolic Syndrome. **2006**, 55-80

58 Mag een patiënt die goed is ingesteld op orale antidiabetica, op zijn verzoek op insuline worden ingesteld?. **2006**, 2126-2127

57 Is er iets op tegen om een sulfonylureumderivaat, metformine en thiazolidinedionen tegelijk te gebruiken?. **2006**, 733-735

56 The Place of Insulin Secretagogues in the Treatment of Type 2 Diabetes in the Twenty-First Century. **2007**, 67-76

1

55 Overview of diabetes mellitus. **2007**, 1-16

54 Insulin Therapy in Type 2 Diabetes. **2007**, 181-206

53 Oral Hypoglycemic Agents. **2007**, 97-105

52 Combination Therapy for Treatment of Type 2 Diabetes. **2007**, 207-226

51 Type 2 Diabetes. **2009**, 33-53

1

50 INSULINS AND OTHER HYPOGLYCEMIC DRUGS. **2009**, 357-473

49 Features of treatment of type 2 diabetes mellitus in patients with concomitant pathology. **2009**, 15, 31-41

48 3-(4-Bromo-phenyl-sulfon-yl)-8-methyl-1,3-diaza-spiro-[4.5]decane-2,4-dione. **2009**, 65, o1892

47 3-(4-Chloro-phenyl-sulfon-yl)-8-methyl-1,3-diaza-spiro-[4.5]decane-2,4-dione. **2009**, 65, o1893

46 Glycemic Goals. **2010**, 645-658

45 Gastrointestinal and Hepatic Manifestations of Systemic Diseases. **2010**, 557-592.e11

44	Determining the Factors that Influence the Insulin Requirements in Type 2 Diabetic Patients. 2010 , 25, 110		2
43	Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin. 2010 , 3, 243-52		
42	How to use Type 2 Diabetes Treatments in Clinical Practice: Combination Therapies. 494-513		
41	Clinical utility of fixed combinations of sitagliptin-metformin in treatment of type 2 diabetes. 2010 , 3, 363-72		2
40	Cost of Pycnogenol Supplementation and Traditional Diabetes Treatments per Unit of Improved Health Outcome. 2011 , 457-465		
39	Recent Advances to Evaluate Anti-Diabetic Medicinal Plants. 2012 , 526-569		
38	Apoptosis in Pancreatic Islet Cells in Type 1 and Type 2 Diabetes. 2013 , 1-24		
37	Apoptosis in Pancreatic Cells in Type 1 and Type 2 Diabetes. 2015 , 845-872		
36	Hormones Part 2: Insulin and Other Glucose-Controlling Medications. 2015 , 327-343		
35	Antidiabetic Activity of Polar and Nonpolar Solvent Extracts from (Willd.) Link Leaves. <i>Pharmacognosy Research (discontinued)</i> , 2017 , 9, 261-265		0.7
34	Role of Glycation in Type 2 Diabetes Mellitus and Its Prevention through Species. <i>BioMed Research International</i> , 2021 , 2021, 7240046	3	0
33	Herbal carbohydrates in healthcare. 2022 , 185-204		
32	Choosing Medications for Type 2 Diabetes [What Weighting Should Be Given to Cardiovascular Risk Reduction?]. 2021 , 174-186		
31	Treatment of the Obese Patients With Type 2 Diabetes. 2006 , 471-486		
30	Diabetes Mellitus. 2008 , 137-176		
29	Introduction to Diabetes. 2006 , 1-37		
28	Advances in diabetes for the millennium: understanding insulin resistance. <i>MedGenMed: Medscape General Medicine</i> , 2004 , 6, 11		1
27	Effects of insulin versus sulphonylurea on beta-cell secretion in recently diagnosed type 2 diabetes patients: a 6-year follow-up study. <i>Review of Diabetic Studies</i> , 2010 , 7, 225-32	3.6	16

26	Evaluation and management of diabetes mellitus. <i>American Health and Drug Benefits</i> , 2008 , 1, 39-48	1.7	2
25	Cost-effectiveness of intermediate or long-acting insulin versus Exenatide in type 2 diabetes mellitus patients not optimally controlled on dual oral diabetes medications. <i>Pharmacy Practice</i> , 2006 , 4, 129-33	1.8	3
24	Therapeutic ultrasound reverses peripheral ischemia in type 2 diabetic mice through PI3K-Akt-eNOS pathway. <i>American Journal of Translational Research (discontinued)</i> , 2016 , 8, 3666-3677	3	10
23	Adherence to oral hypoglycemic medication among patients with diabetes in Saudi Arabia. <i>International Journal of Health Sciences</i> , 2017 , 11, 45-49	1.1	6
22	The prevalence of urinary tract infections in type 2 diabetic patients: a systematic review and meta-analysis.. <i>European Journal of Medical Research</i> , 2022 , 27, 20	4.8	4
21	Purification, structural characterization, and bioactivities of a polysaccharide from <i>Coreopsis tinctoria</i> . <i>Food Frontiers</i> ,	4.2	0
20	Metformin Protects against Diabetic Cardiomyopathy: An Association between Desmin β comere Injury and the iNOS/mTOR/TIMP-1 Fibrosis Axis. <i>Biomedicines</i> , 2022 , 10, 984	4.8	3
19	Oligomeric Proanthocyanidin Complex from Avocado Seed as A Promising α -glucosidase Inhibitor: Characteristics and Mechanisms. <i>Planta Medica</i> ,	3.1	
18	Overproduction, Purification, and Stability of the Functionally Active Human Carnitine Acetyl Transferase. <i>Molecular Biotechnology</i> ,	3	0
17	Exploring the plant-derived bioactive substances as antidiabetic agent: An extensive review. <i>Biomedicine and Pharmacotherapy</i> , 2022 , 152, 113217	7.5	8
16	Antidiabetic Potential of α -Carthamus oxycantha α ; M.Bieb. Seeds in Alloxan Induced Diabetic Rats. <i>Pharmacology & Pharmacy</i> , 2022 , 13, 189-198	0.3	
15	Part Three: A Brief Primer of Non-Insulin Treatments for Type 2 Diabetes Mellitus in Older People. 2022 , 37, 251-259		1
14	Effects of GH on the Aging Process in Several Organs: Mechanisms of Action. <i>International Journal of Molecular Sciences</i> , 2022 , 23, 7848	6.3	0
13	Polypharmacology in Clinical Applications: Metabolic Disease Polypharmacology. 2022 , 199-229		
12	Genetic and Phenotypic Factors Affecting Glycemic Response to Metformin Therapy in Patients with Type 2 Diabetes Mellitus. 2022 , 13, 1310		
11	PHARMACOLOGIC MANAGEMENT OF THE PATIENT WITH TYPE 2 DIABETES. 2001 , 36, 217-242		2
10	From an Apple to a Pear: Moving Fat around for Reversing Insulin Resistance. 2022 , 19, 14251		0
9	Weight Management, Micronutrients, and Supplements in Diabetes.		0

8	New Metformin Citric Acid Pharmaceutical Molecular Salt: Improving Metformin Physicochemical Properties. 2022 , 12, 1748	2
7	Role of natural mTOR inhibitors in treatment of diabetes mellitus.	0
6	Pathological and Biochemical Investigation of the Effects of L-Carnitine and Gemfibrozil, Peroxisome Proliferator Activated Receptors (PPARS), Oxidative Stress and Lipidosis in High Fat Diet Rabbits.	0
5	Alleviating effects and mechanisms of action of large-leaf yellow tea drinking on diabetes and diabetic nephropathy in mice. 2023 , 12, 1660-1673	0
4	Oral empagliflozin-loaded tri-layer core-sheath fibers fabricated using tri-axial electrospinning: Enhanced in vitro and in vivo antidiabetic performance. 2023 , 635, 122716	1
3	Formulation of novel niosomal repaglinide chewable tablets using coprocessed excipients: in vitro characterization, optimization and enhanced hypoglycemic activity in rats. 2023 , 30,	0
2	Legume-Derived Bioactive Peptides in Type 2 Diabetes: Opportunities and Challenges. 2023 , 15, 1096	0
1	Role of obesity related inflammation in pathogenesis of peripheral artery disease in patients of type 2 diabetes mellitus.	0